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Abstract
Regeneration of injured peripheral nervous system (PNS) axons is a widely ob-
served, but incompletely understood phenomenon. While PNS axons are capable of
spontaneous regeneration, functional recovery may be di cult to achieve. The com-
plex in vivo environment provides a challenging setting to examine axonal injury and
regeneration, making reductionist in vitro approaches necessary. Cell culture-based
injury platforms allow for injury of individual axons while organotypic platforms
more closely resemble the in vivo injury environment. This dissertation presents
the development and application of novel compartmentalized in vitro platforms, first
presenting cell culture devices and culminating with an organotypic (slice culture)
platform, to enable study of the site of action of degenerating and regenerating com-
pounds on PNS axons. First, microfluidic devices were utilized to determine that
the chemotherapeutic agent paclitaxel is most destructive when applied to the axon,
and that this chemotherapy-induced axonal degeneration can be limited by applica-
tion of erythropoietin to either the cell body or axon, indicating that local mecha-
nisms can be counteracted through cellular mechanisms. Next, regenerative e↵ects of
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members of the glial cell-line derived nerve growth factor (GDNF) family of ligands
(GFLs) were investigated in a microfluidic physical injury model. All tested GFLs
enhanced regeneration regardless of site of application, with GDNF showing the most
enhancement. Concurrent application of a retrograde transport blocker with GDNF
diminishes this regenerative e↵ect, indicating the importance of cellular rather than
local mechanisms. Finally, a two-compartment culture device that enables control
of the local environment of regenerating adult motor axons was developed and opti-
mized, and functional compartmentalization demonstrated. This device is the first of
its kind and allows for tailoring of the immediate environment of adult motor axons
regenerating within the three-dimensional structure of peripheral nerve. The ability
to study axonal injury and regeneration in such highly tailorable environments will
lead to more comprehensive understanding of injury and regeneration, aiding eventual
goals of improving reinnervation accuracy and surgical outcomes.
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Peripheral axon injury and regeneration is widely observed, yet poorly understood.
The inherent complex design of the nervous system necessitates the use of reductionist
in vitro devices that enable a systematic probing of cellular processes. Here I will
provide context for my thesis by providing a general overview of nervous system
structure and anatomy, an overview of compartmentalized devices, and a discussion of
current approaches and challenges to treating peripheral nerve injury. I will conclude
this overview chapter with a discussion of my goals, specific aims, and the organization
of my dissertation. Separate abstracts and introductions precede Chapters 2-6 in
order to provide a more specific overview relevant to those chapters.
1
CHAPTER 1. INTRODUCTION
1.2 Nervous System Structure
An understanding of the general organization and components of the nervous
system is necessary for insight into di culties that may arise during nerve injury
and regeneration. The nervous system is categorized into the central nervous system
(CNS) and the peripheral nervous system (PNS). The CNS serves as a control center,
conducting and interpreting signals, and consists of the brain and spinal cord, while
the PNS consists of nerves, both motor (e↵erent) and sensory (a↵erent), that transmit
signals between the CNS and the rest of the body. Neurons are the functional units
of the nervous system and do not undergo mitosis, while glial cells are the support
cells of the nervous system and much more plentiful than neurons. Schwann cells are
the principle glial cells of the PNS, while oligodendrocytes, astrocytes, and microglia
are the glial cells of the CNS. These cells will be gone into further detail in the next
chapter.
The spinal nerves of the PNS originate from the spinal cord, a schematic of which
can be seen in Figure 1.1. The spinal cord contains central butterfly-shaped grey
matter made up of the cell bodies of excitatory neurons, CNS glial cells, and blood
vessels. Surrounding the grey matter is insulting and protective white matter consist-
ing of axons and glial cells of the CNS. Oligodendrocytes myelinate the axons, while
astrocytes help form the blood-brain barrier. Axons project from the white matter
in fascicles, travel through the PNS-CNS transition zone, and enter the PNS. In the
transition zone, the glial cells of the CNS are separated from the glial cells of the PNS.
2
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The nerves exiting the sides of the spinal cord can be divided into subgroups, with
the ventral root carrying motor signals from the CNS and the dorsal root carrying
sensory information to the CNS. The cell bodies of the sensory neurons are located
in dorsal root ganglia (DRG) located along the dorsal root while the cell bodies of
motor neurons are located within the spinal cord as can be seen in the schematic in
Figure 1.1. As axons can be on the scale of meters long in the PNS, the cell bodies
of these peripheral neurons may experience drastically di↵erent environments from
their distal axons. The spinal nerve contains contributions from both motor and sen-
sory neurons and is thus a mixed nerve. Along with the neurons, these peripheral
nerves are bundled together with support tissue. Endoneurium is composed mainly
of oriented collagen fibers surrounds individual axons, while perineurium is composed
primarily of fibroblasts and collagen and surrounds groups of axons to form fascicles.
Epineurium is made up loose fibrocollagenous tissue encases fascicles to form a nerve
trunk. Capillaries within the support tissue and other penetrating vessels ensure that
the nerve trunk is well vascularized.
The neurons that make up a nerve can be further subdivided into the soma (cell
body), dendrites, and the axon, as can be seen in Figure 1.2. Signals typically propa-
gate from the axon of one neuron to the dendrite of another, connecting at a synapse
. While a typical neuron may have many dendrites, a neuron generally has one axon
from one point of origin, although it may later branch. The cell body of a neuron
contains its nucleus and is the location of protein synthesis. Dendrites are branched
3
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Figure 1.1: Schematic of a transverse section of spinal cord
cellular extensions from the cell body. In contrast to dendrites, axons can be ex-
tremely long in the peripheral nervous system and can have lengths on the order of
meters. These axons contain cytoplasm and are provided structure by microfilaments
and microtubules. Here, the microtubules are important not only with regard to
structure, but also to growth and axonal transport. Axonal transport is an essential
function, as it involves not only the transport of proteins and organelles from the
cell body to the axon, but also for removing waste molecules at the distal axon by
the cell body. Axonal transport is accomplished through motor proteins which bind
to both the microtubules and potential cargo. Kinesin is responsible for anterograde
transport from the soma to the distal axon, while dynein is responsible for retrograde
transport from the distal axon back to the soma. Disruption of this axonal transport
4
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can potentially trigger nerve degeneration. Nerve injury neurobiology, and particu-
larly how it di↵ers in the CNS as compared to the PNS, will be discussed in further
detail in the next chapter.
Figure 1.2: Schematic of neuronal structure indicating the important role of micro-
tubules in axonal transport. Modified from [3].
1.3 Compartmentalized Platforms for
Neuronal Studies
The Campenot Chamber was the first device to demonstrate individual manipu-
lation of cell bodies and axons in PNS neurons [4]. Demonstrated in the schematic in
Figure 1.3, a Teflon divider attached to a collagen coated glass petri dish sealed with
5
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silicon grease served to separate cell bodies from axons, while cuts made in the glass
dish served to guide axons. The isolated compartments can then be independently
manipulated by adding growth factors or other proteins. These devices allowed for the
first site of action studies, but they are prone to leakiness and irreproducibility from
device to device. More recent neuronal studies have focused on compartmentalized
microfluidic systems fabricated through poly(dimethylsiloxane) (PDMS) soft lithogra-
phy, which allow for fluidic isolation of axonal chamber from somal chamber through
microliter level volume di↵erences between the two chambers, while microchannels
between the chambers provide high fluidic resistance that leads to a small but sus-
tained flow that counteracts di↵usion [5–8]. These devices are highly reproducible
and many can be fabricated easily. The utilization of such a system, with an incorpo-
rated physical injury modality, will enable the study of the regeneration environment
of single axons. These types of culture systems have high reproducibility and ease of
fabrication, and allow for isolation of molecular mechanisms.
Applying the concept of creating dual compartments to organotypic cultures ex-
tends the e cacy further. Organotypic cultures are useful for motor neuron studies
due to di culties maintaining these cells in monolayer cultures (which involve plating
of dissociated cells) for longer periods [9]. In Figure 1.4 we see a comparison of mi-
crofluidic cultures and organotypic cultures to other commonly used commonly used
techniques for studying nerve injury. While cell culture devices such as Campenot
chambers and their microfluidic counterparts allow for compartmentalized exposure
6
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Figure 1.3: The Campenot Chamber, the first compartmentalized device for neuronal
cell culture, consisted of a teflon divider attached to a glass petri dish with silicon
grease. Neurons can be seeded in one compartment (A), and neurites extend into
other compartments by following scratches made on the surface of the glass. These
compartments can be individually manipulated (in this example with nerve growth
factor (NGF) added to compartment C with B serving as a control). Modified with
permission from [1].
through fluidic isolation, these do not reproduce the three dimensional structure of
nerve and thus cannot accurately model nerve repair. One of the aims of this thesis
is to address the unmet need of a compartmentalized organotypic injury platform.
The Brushart lab has developed an in vitro model of adult mammalian nerve
repair in an organotypic co-culture system [10]. Organotypic cultures are prepared
from nervous tissue without dissociation and thus preserve three-dimensional cytoar-
chitecture within tissue slices [11]. This concept is applied to spinal cord slices and
peripheral nerve, in order to create a co-culture system amenable to nerve repairs. In
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Figure 1.4: Comparison of nerve injury investigation methods. Comparing across
multiple commonly used techniques for studying nerve injury from least to most
complex (top to bottom), microfluidic cultures and organotypic cultures provide an
intermediate complexity between simple monolayer cultures and in vivo models while
allowing for more precise control and monitoring. The unmet need of an organotypic
platform that allows for selective control of the axon versus the soma is addressed in
this thesis.
order to isolate the e↵ects of growth factors, there is a need to further modify this
system in order to minimize di↵usion and allow isolated exposure of growth factors to
regenerating axons. While monolayer cell culture devices allow for compartmental-
ization through fluidic isolation, there are no such devices for the organotypic spinal
cord and peripheral nerve co-culture. The development of such a device would allow
for the study of axon specific mechanisms of motor axon regeneration by allowing for
control of the local environment of regenerating axons within an in vitro device that
more closely replicates an in vivo three-dimensional environment.
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1.4 Current Approaches and Challenges
The current treatment for peripheral nerve injury is end-to-end surgical recon-
nection for smaller defects, or reconnection with an autologous nerve graft for larger
ones. Direct reconnection cannot be used for larger defects due to resulting tension
in the nerve that may inhibit regeneration. There is a need for improving surgical
outcomes and functional recovery.
A potential method to enhance regeneration is through utilizing growth factors.
Elucidating the role of pathway-derived growth factors is crucial to promoting re-
generation of motor neurons and improving surgical outcomes. A schematic of the
post-injury environment for regenerating peripheral nerve can be seen in Figure 1.5.
Notably, we see that Schwann cells increase their production of growth factors as a
response to injury, and this is thought to play a role in modality-specific regenera-
tion. Regenerating motor axons preferentially reinnervate muscle pathways, indicat-
ing the ability of regenerating motor axons to distinguish between motor and sensory
nerve [12]. This information may help explain why grafting motor nerve with cu-
taneous nerve consistently produces worse results than end-to-end nerve repair [13].
While it has been shown that throughout regeneration growth factors can vary as a
consequence of peripheral pathway or type of Schwann cell, it is not clear which of
these factors are responsible for the modality-specific support of regenerating motor
axons in muscle nerve or ventral root. [14,15]. Growth factor e↵ects are best studied
in vitro, in a simplified environment in which growth factor specific e↵ects on axons
9
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and cell bodies can be teased out. Thus, the development of a platform that both
closely mimics and allows precise control over the post-injury in vivo regeneration
environment would be very valuable.
Figure 1.5: The regeneration environment of an injured peripheral nerve can be very
complex. Notably, Schwann cells upregulate their production of growth factors, which
are thought to play a role in modality-specific regeneration. A method to be able to
precisely model the post-injury regeneration environment is thus extremely valuable.
This figure was reproduced with permission from [2], with minor modifications.
1.5 Specific Aims
In my dissertation, I present the design and application of novel in vitro platforms,
both organotypic and cell-culture based, to enable the study of nerve injury and
regeneration in locally tailorable environments. This will include microfluidic devices
that enable chemical injury and physical injury, and an organotypic device that allows
10
CHAPTER 1. INTRODUCTION
for both physical and chemical injury in a more three-dimensional environment. My
specific aims are:
Aim 1 Determine site of toxicity of paclitaxel-induced degeneration
Aim 2 Determine the site of action of glial cell line-derived neurotrophic factor
(GDNF) family ligands in enhancing regrowth after axotomy
Aim 3 Develop a dual chamber organotypic spinal cord and peripheral nerve co-
culture device
In further detail:
Specific Aim 1: Determine the site of toxicity of paclitaxel-induced degeneration
Background: Paclitaxel is a commonly used chemotherapeutic agent that has been
shown to cause distal polyneuropathies. These symptoms are often a dose-limiting
e↵ect of paclitaxel for cancer patients. Although the mechanism is not clear, it is
hypothesized that paclitaxel may induce distal axonal degeneration by disrupting
microtubule-based axonal transport. Erythropoietin (EPO) is a glycoprotein hor-
mone known to have several di↵erent roles in the body, including neuroprotection.
Rationale: Utilizing microfluidic devices, we can elucidate the site of action of pacli-
taxel, whether cell body or axon, and the most e↵ective site of neuroprotection. If we
can determine if paclitaxel is most destructive when applied locally to either the cell
body or distal axon, it will help elucidation of a mechanism of action as well as have
implications for delivery of chemotherapeutics in order to limit axonal degeneration.
11
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We hypothesize that paclitaxel will be most destructive when applied locally to the
axon more so than the soma. If disruption of axonal transport is the likely cause of
axon toxicity, local application to distal axons should be most destructive. If EPO’s
neuroprotective e↵ects can occur through local mechanisms, it would be expected
that localized application will be most e↵ective, while if these mechanisms require
transport to the cell, application the the soma will be most e↵ective.
Specific Aim 2: Determine the site of action of glial cell line-derived neurotrophic
factor (GDNF) family ligands (GFLs) in enhancing regrowth after axotomy
Background: Many growth factors are upregulated in the distal pathway post-injury.
GDNF is one such growth factor that has been shown to promote regeneration both
in vitro and in vivo. The site of action of the regenerative e↵ects of GDNF has not
been clearly demonstrated. More so, it would be interesting to determine if other
members of the GDNF family of ligands can demonstrate a similar enhancement of
regeneration post-injury.
Rationale: By performing axon injury within a microfluidic device, we can investigate
whether any regenerative e↵ect of GFLs on sensory axons are due to local or cellular
mechanisms. We hypothesize that if these growth factors occur through cellular
mechanisms, application to the cell body side would be most e↵ective. This can be
further confirmed by concurrent administration of a retrograde transport blocker to
determine if growth factor application to the injured axon requires transport back to
the cell. In addition, extrapolating GDNF to a tissue-level sensory nerve injury model
12
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may not have similar results to our cell-level study as there are many support cells
and extracellular matrix components that may change the situation considerably.
Specific Aim 3: Develop a dual chamber organotypic spinal cord and peripheral
nerve co-culture device
Background: There is an unmet need for an organotypic nerve repair model that
allows for isolation of the regrowing axon in order to precisely tailor the local envi-
ronment without disrupting cell bodies. Growth factor e↵ects are best isolated in
vitro, however, monolayer cell culture techniques do not allow for an accurate model
of nerve repair. Organotypic culture allows us to perform experiments at the tissue
level where it is possible to recreate a nerve repair environment.
Rationale: A novel device can be designed that includes a spinal cord and peripheral
nerve co-culture in order to create a nerve injury platform that allows for indepen-
dent manipulation of the regenerating axon versus neuronal cell bodies. Injury can be
performed by simple transection, while nerve repair can be performed by the addition
of new grafts. The device requires viability of cells and axons, as well as demonstra-
tion of functional compartmentalization. We hypothesize that such a device can be
created using common themes from both microfluidic and Campenot culture systems
in a way that ensures viability, repeatability, and compartmentalization.
13
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1.6 Significance and Innovation
The engineering innovation of the proposed project is that this is the develop-
ment of the first dual chamber organotypic co-culture platform, isolating areas of an
embedded membrane, for spinal cord and peripheral nerve co-culture. There is a
need for an experimental model that both reproduces the complex three-dimensional
environment of peripheral nerve and allows for precise control of the growth factor
environment in the distal pathway.
The biological significance is that these studies will contribute to the current
knowledge of degenerative chemotherapeutic agents and the role of GFLs in the re-
generation of PNS axons, as well as demonstrate the feasibility of utilizing these
devices for further pathway-derived growth factor studies on injured neurons. Ex-
amining the regenerative e↵ects of pathway-derived growth factors on regenerating
motor axons, as well as on healthy, injured, and regenerating sensory axons will help
fill gaps in current biological knowledge, and may prove fruitful in the development
of therapies for enhancing successful and accurate regeneration post-injury.
1.7 Dissertation Organization
The organization of this thesis is as follows:
Chapter 2 provides a more comprehensive nerve injury neurobiology overview,
followed by a discussion on microfuidic devices for studying nerve injury. Chapters
14
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3-5 will detail the work for my aims. More specifically, Chapter 3 presents the de-
termination of the site of toxicity of the chemotherapeautic agent paclitaxel through
a microfluidic chemical injury device and demonstrates neuroprotection through the
glycoprotein hormone erythropoietin. Chapter 4 provides a study on the determina-
tion of the site of action of GFLs in promoting axonal regeneration through a mi-
crofluidic physical injury device and extends that study to the tissue scale. Chapter
5 discusses the development of a compartmentalized organotypic device for studying
nerve regeneration. Finally, Chapter 6 concludes with a discussion of the significance,
major contributions, and future directions.
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Chapter 2
Investigation of Nerve Injury
through Microfluidic Devices
This review has been published in the Journal of the Royal Society of Interface [16]
and reprinted in accordance with the guidelines of the journal.
2.1 Abstract
Traumatic injuries, both in the central nervous system and peripheral nervous
system, can potentially lead to irreversible damage resulting in permanent loss of
function. Investigating the complex dynamics involved in these processes may elu-
cidate the biological mechanisms of both nerve degeneration and regeneration, and
may potentially lead to the development of new therapies for recovery. A scientific
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overview on the biological foundations of nerve injury is presented. Di↵erences be-
tween nerve regeneration in the central and peripheral nervous systems are discussed.
Advances i n microtechnology over the past several years have led to the development
of invaluable tools that n ow facilitate investigation of neurobiology at the cellular
scale. Microfluidic devices are explored as a means to study nerve injury at the neces-
sary simplification of the cellular level, including those devices aimed at both chemical
and physical injury, as well as those that recreate the post-injury environment.
2.2 Introduction
Nerve injuries can often cause devastating functional disabilities. Fortunately, pe-
ripheral nerves hold the potential to regenerate after injury, however complete repair
and exact functional restorations are not possible. Current state of the art treatment
for peripheral nervous system (PNS) injuries involves end-to-end suturing of unin-
jured nerve ends when the injury is small, and the use of autologous nerve grafts
when the injury is large. The use of autologous nerve grafts in clinical peripheral
nerve repair is associated with donor site morbidity, the need for multiple surgeries,
limited tissue availability, and inadequate functional reinnervation [17–19]. Regen-
eration is not inherently possible in the central nervous system (CNS) environment,
and hence no pharmacological or technological solutions to the CNS repair and re-
generation are available [20,21]. Accordingly, there is a considerable research interest
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in studying both nerve injury and regeneration in order to elucidate how to promote
successful nerve repair. Investigating nerve injury on a cellular scale o↵ers a unique
potential for probing the pathophysiology of injury at the single neural cell level and
investigating neural responses to the immediate environment. Traditional in vitro
cell culture techniques have contributed significantly to our understanding of healthy
and diseased neurons [22, 23]. However, these techniques do not provide a controlled
environment to grow or guide neurons, or enable precise probing of the cells and eval-
uation of extracellular or environmental interactions. Modern microfluidic technology
o↵ers the potential to accurately model or control the changing neuronal microenvi-
ronments. Thus, the precision and control supplied by microfluidic technology may
be particularly relevant for the study of nerve degeneration and regeneration.
Neurons naturally operate in the microscale as multistate mechanical, chemical,
and electrical sensors and actuators. Their operations occur on a level fundamentally
familiar to engineers, and in a way that makes interfacing of neuronal cells with mi-
crodevices intuitive [24]. Application of microtechnology or micro electromechanical
systems (MEMS), has contributed greatly in the past several years, and o↵ers invalu-
able tools to facilitate neuroscience studies at the cellular scale. This technology has
led to the development of Lab-on-a-Chip (LOC) devices, built using microtechnology,
incorporating elements such as microscale channels, pumps, and valves, and o↵ering
precise control or manipulation of the neuronal microenvironment in ways previously
unachievable with macro-scale methods [5,6,25,26]. In view of their potential, innova-
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tive LOC microdevices have been developed to o↵er a highly structured environment
to experiment with neuronal cells. These LOC devices o↵er spatial control at the
level of cell deposition within designed structures, separation of subcellular compo-
nents through the use of microchannels, and influence over interactions with other
cell types [7,24,27–32]. There is also the benefit of precise control over the amount of
reagents or factors added to the cells and low cost associated with the devices due to
the small volume of expensive reagents required for the devices. There has been some
application of microtechnology to in vivo implantable devices for nerve regeneration,
such as those that incorporate microfluidic chips into nerve implants in order to pro-
vide precise delivery of a target drug or enable monitoring of regeneration [33–37].
However, the majority of neuronal LOC devices are in vitro devices, in contrast to in
vivo cell or whole-organism devices, and will be the primary focus of this review.
While studying neurons in their healthy state is undoubtedly valuable, experi-
mentation into the mechanistic understanding of the underlying pathways governing
axonal injury and regeneration, a research area of great importance, is less developed
and would benefit from advances in the LOC technology [38]. Our intent is to give
an overview of the biology of nerve injury and explore microfluidic LOC devices that
accurately and selectively injure axons or model the post-injury environment and ex-
amine their potential in the field of regenerative neuroscience. Utilization of these
types of LOC devices will enable a deeper understanding of axonal injury and re-




2.3 Biology of Nerve Injury and
Regeneration
The physiology of the nervous system presents distinctive challenges to nerve
regeneration. An understanding of the general organization and components of the
nervous system is necessary for insights into di culties that may arise during nerve
injury and regeneration. The nervous system is categorized into the CNS and the
PNS. The CNS consists of the brain and spinal cord, and serves as the control center,
conducting and interpreting signals, while the PNS consists of motor and sensory
nerves that transmit signals between the CNS and the rest of the body. The nervous
system consists mainly of neurons and glial cells. Neurons, the basic functional units,
are made up of a soma (cell body), axons that conduct signals away from the soma,
and dendrites that relay signals to the soma. Axons contain the majority of the cells
cytoplasm [39]. Glial cells are the support cells of the nervous system, and are much
more plentiful than neurons. These cells have some capacity for cell division, unlike
neurons which cannot undergo mitosis and proliferation, although they can regenerate
or sprout processes under the right conditions [17]. Schwann cells are the glial cells of
the PNS, while oligodendrocytes, astrocytes, and microglia are the glial cells of the
CNS. Schwann cells form the myelin sheath that insulates peripheral axons. Schwann
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cells ensheath axons and the myelin sheath forms concentric layers around the axon,
which become tightly apposed. Oligodendrocytes myelinate axons of the CNS, and
in contrast to Schwann cells, can myelinate several axons each. Another important
distinction is that in the PNS, Schwann cells are surrounded by a neurilemma, which
is a basement membrane (basal lamina) similar to the type found in epithelial layers.
These characteristic di↵erences can be found summarized in Figure 2.1. The presence
of a basal lamina is one of the distinguishing features of the PNS, as CNS axons do
not have this continuous basal lamina surrounding their axons [17, 40]. The absence
of a basal lamina may contribute to regenerative failure in the CNS, as the basal
lamina not only provides access to growth promoting ECM molecules, but may also
shield the axons from inhibitory molecules [41].
Upon axonal injury, either through transection or severe compression, axon patho-
physiology may proceed through di↵erent paths. The axon can undergo a degenerative
retraction from the site of injury for a relatively short distance unless the injury is
close to the cell body, in which case it proceeds to the cell body where retrograde
neuronal degeneration can occur. Otherwise, Wallerian degeneration (WD) of the
distal segment occurs, characterized by axonal swelling followed by accumulations of
spheroids, and disruption of the cytoskeleton [38]. WD can be described as a series
of cellular events that lead to anterograde degeneration of axons and myelin sheaths
from the site of lesion to the nerve endings, while the proximal stump undergoes
regeneration. A major di↵erence between PNS and CNS neurons is the response to
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Figure 2.1: A typical CNS neuron is myelinated by oligodendrocytes, with have the
capacity to myelinate several cells at once, while a PNS neuron is myelinated by
Schwann cells, which myelinate in a one-to-one ratio and are surrounded by basal
lamina (reproduced with permission from [40]).
axotomy and injury [17, 38, 42–45]. In the CNS, regeneration does not occur in the
native environment, while in the PNS regeneration does occur, although complete
functional recovery may not. The inherent ability of PNS neurons to regenerate con-
trasting with the inability of CNS neurons to regenerate has been a long-standing
area of research interest. Injury to the axon reactivates an intrinsic growth capacity
in the cell body [46]. In the PNS, in contrast to the CNS, this intrinsic growth capac-
ity is coupled with a locally permissive environment due to a more successful clear-
ance of axonal and myelin debris from the degeneration process by Schwann cells and
macrophages, as well as support from axon guidance cues, such as extracellular matrix
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(ECM) components, cytokines, and growth factors [47]. Figure 2.2 gives a high-level
summary of the di↵erences in CNS and PNS injury and regeneration, demonstrating
successful regeneration following injury in the PNS with the aid of Schwann cells,
circulating monocytes, and macrophages, contrasted with scar formation in the CNS.
The following is meant to be an overview of injury and regeneration in order to pro-
vide the rationale and context for the development of neuronal LOC devices; further
sources can be consulted for an in-depth biological review [17,19, 38, 41–50].
2.3.1 PNS Injury and Regeneration
Peripheral nerve injuries (PNIs) can result from stretch-related injuries, lacera-
tions, or compressive trauma [50]. While these types of injuries can all lead to WD,
there is typically more preservation of continuity of the neuron with stretch-related
and compressive injuries, particularly with regard to the basal lamina, although dis-
ruption of this continuity can also be seen in extreme cases [42]. This preservation of
continuity of the basal lamina can increase the probability of successful regeneration.
Laceration models are seen proportionately more often in the literature due to their
ease of reproducibility.
Depending on the extent and site of injury, changes occur at the soma, site of
injury, and axon segments proximal and distal to the site of injury. Within hours
of injury, axons and myelin start to physically fragment and swell, inhibiting signal
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Figure 2.2: A comparison of (a) PNS Regeneration demonstrating a favorable regen-
eration environment cleared of debris by Schwann cells and macrophages, with (b)
the CNS post-injury environment, which includes unsuccessful debris clearance and
scar formation (adapted from [50] by [17], reproduced with permission from both).
conduction. In the soma, the nucleus moves towards the periphery of the cell body
and there is an increase in cell volume as production of RNA and regenerative proteins
increases [49]. Somal proximity to the site of injury and age of the subject determines
neuronal survival; the closer the injury is to the cell body and the older the subject,
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the more susceptible the neurons will be to apoptosis, with the exception of enhanced
sensitivity of neurons to apoptosis in neonates [49, 50]. Similar to WD, the proximal
segment undergoes minimal degradation, called traumatic degeneration, depending
on the extent of injury. If the injury is su ciently severe, or proximal to the cell body,
this degradation can extend back to the cell body leading to cell death [49]. Schwann
cells become active and proliferate, forming dedi↵erentiated daughter cells that release
molecules to help in the degeneration and regeneration process and remove axonal and
myelin debris from the site of injury together with macrophages. Distal to the site of
injury, focal lesions can trigger WD. These focal lesions need not be transections, but
do need to cause a focal block of anterograde axonal transport, such as with a severe
compressive injury or transection [44]. Late in the WD process, Schwann cells align
themselves in columns along the intact basement membrane, known as the bands of
Bunger, serving to guide sprouting axons during regeneration.
The WD process needs to complete before nerve regeneration can occur in severe
injuries, however in mild injuries depending on proximity to the cell body, regenera-
tion can begin nearly immediately. Regeneration has been found to be dependent on
responses from the cell body, depending on a variety of factors including the age of
the subject, severity of lesion, distance from the cell body, location of the injury, and
availability of pathway-derived growth factors [51]. The first signs of regrowth may
be visible several weeks post-injury for more severe injuries, or as early as 24 hours
post-injury for milder injuries [50]. The proximal axon produces multiple sprouts
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containing growth cones, normally present during development, that initiate regener-
ation [38,50]. The reformed growth cones can encounter negative cues such as physical
barriers, molecular barriers, and other inhibitory factors. Physical barriers can in-
clude glial cells within the site of injury, while molecular barriers include chondroitin
sulfate proteoglycans [52]. The regenerating growth cones become misdirected as they
attempt to avoid these barriers, and thus become unsuccessful in making connections
to target tissues. The growth cone, similar to that in the developmental state, can
also be positively guided towards targets through both soluble and bound tropic cues,
including growth factors.
The growth cones have an a nity for laminin and fibronectin, ECM components
of the basal lamina of the Schwann cell tubes, and use these for guidance. Once
contacted, the regenerating axons preferentially grow within these tubes towards the
end organ. Schwann cells along the Bands of Bunger also increase production and
release of factors such as nerve growth factor (NGF) that act as stimuli for contin-
ued axon regrowth and additional guidance cues [50]. Growth factor signaling has
traditionally been known to play roles in development, but the role of such signaling
has recently been extended to regeneration as well [53]. Far less is known about the
role of pathway-derived growth factor signaling in the response of regenerating adult
neurons, and the signaling pathways involved in each case may be di↵erent [54].
The nature of the site of damage can influence the success of regeneration by
a↵ecting growth cones, and can vary based on extent of injury. In a transection there
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may be a gap and an extended lesion site, and thus more chances for scarring and space
for wandering axons [38]. Outlook for functional recovery after transections that cause
a large gap between proximal and distal ends can be negligible. When a nerve repair
is performed, post suturing, there can be scarring or poor matching. In contrast, a
nerve crush may yield a more favorable setting for regeneration and reinnervation,
since the internal structure and surroundings are preserved [38]. Human peripheral
axon regeneration rates have been reported to range around 1 mm/day in clinical
situations, with further diminishing rates over time [17, 38, 50]. These rates may
vary depending on the extent of injury, as well as the type, with higher rates of
regeneration in crush injuries and lower rates in transection injuries; regeneration
rates expectedly also vary across species. Axonal regeneration does not always mean
functional recovery, as misdirection of regenerating axons is common cause of poor
functional recovery. In vitro studies of peripheral nerve injury and regeneration are
valuable in order to elucidate the roles of growth factors in regeneration, as well as
to observe how to enhance regeneration rates and functional reinnervation.
2.3.2 CNS Injury and Regeneration
CNS axon injury can result from the mechanical forces associated with the rapid
deformation of the brain or spinal cord during trauma. Blunt trauma may cause
vascular rupture, decrease the integrity of the blood-brain-barrier, and directly crush
nerves or, in the case of severe force, cause complete axotomy [55]. Edema can also
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result from trauma, with cytotoxic swelling of neurons, which can in turn cause com-
pression of further tissue. Despite the availability of in vivo models, mechanistic
understanding of the underlying pathways governing CNS axonal injury remains only
partially understood. As regeneration does not occur in the native environment of the
CNS, performing injury studies within an in vitro platform may help elucidate the
mechanisms underlying both axonal injury and regeneration. These types of injuries
also share common features and potentially convergent pathways with other condi-
tions that may result in CNS axonal degeneration, including Alzheimers, HIV related
dementia, and multiple sclerosis [44]. There is a need for complete understanding of
the degeneration process, as severity of axon damage plays a large role in eventual
outcomes following degeneration [56, 57].
Focal injuries result from high impact rapid events such as blows to the head,
or projectile and penetrating blast injury. Focal injuries can cause hematomas or
hemorrhaging that in turn cause further compression [44]. When an object impacts
the head, there is an initial focal contact force, and this force may in turn accelerate
or decelerate the brain, causing further inertial forces. Focal lesions can trigger WD
of distal axons. While dynamic deformation rarely leads to primary axotomy, there
does not need to be a complete transection of the axon, as a focal block of axonal
transport may be enough to trigger degeneration [44,58]. Di↵use injuries result from
inertial forces and rapid head rotations, as would occur during car accidents and falls
[59,60]. Di↵use axonal injury (DAI) is multifocal, with multiple spheroids appearing
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on individual axons, and is characterized by swollen and disconnected axons. The
extent of injury is dependent on the mode, severity, duration, and rate of the strain,
as well as the distance of the injury from the cell body, anatomical location of the
injury, and the mechanical properties of the axon [44, 61]. Axons are viscoelastic
and can withstand varying degrees of stretch deformation under normal activities,
but are thought to become brittle under dynamic loading conditions, making them
vulnerable to damage [58]. The mechanical properties of the axon can also vary with
age, previous injuries, and disease. Mechanically stretching cultured axons has been
demonstrated to replicate the morphological and structural changes associated with
DAI [62].
Damage to the axonal cytoskeleton or a primary axotomy can result from a rapid
unidirectional stretch. While it is clear that primary injury results from the direct
mechanical strain experienced by cells from injury, the mechanism of the downstream
cellular events is not well understood. Changes in molecular gradients occur, as there
is sodium influx following injury, which increases swelling and also increases intracel-
lular calcium levels, which may activate proteases for breaking down the cytoskele-
ton [44, 63]. Axonal transport proteins may accumulate in the areas of swelling due
to disruptions in transport, including amyloid precursor protein (APP). Cytoskele-
tal changes are more apparent upon direct damage to the axolemma, which would
occur in severe injury, and it would be beneficial to study these in vitro. Recent
evidence has also indicated axon-specific degeneration pathways separate from those
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related to the cell body, making it beneficial to study axon injury while being able
to manipulate the cell body and axon independently [44, 45, 64, 65]. The determina-
tion of axon-specific pathways may be important for understanding the cellular and
molecular mechanisms for degeneration.
Immediately after injury, CNS axons can display abortive regeneration with an
initial outgrowth for up to 0.5 mm, but then come to a stop and die-back and retract
or become arrested and form retraction bulbs [38]. It has been demonstrated that
CNS neurons can express their intrinsic growth capacity on permissive substrates
within the right biological environment, but the growth appears to be too slow for
full functional reinnervation [66]. Aguayo initially demonstrated that peripheral nerve
grafts can be used to promote CNS axon regeneration [67]. It has also been demon-
strated that peripheral nerve grafts are the most promising grafts for CNS nerve
repair, promoting regeneration from non-permissive white matter to permissive grey
matter in spinal cord repair [68]. The natural CNS environment is regarded as un-
favorable with inhibitory e↵ects from glial scars, chondroitin sulfate proteoglycans
(CSPGs), and myelin-associated proteins, inadequate inflammatory responses, and
hindered debris clearance due to the presence of the blood-brain-barrier. Glial scars
formed at the site of an injury act as both mechanical and biochemical barriers for
regrowing axons. As the name suggests, the scar is often comprised of glial cell types
including reactive astrocytes, microglia, oligodendrocyte precursors, and fibroblasts.
It also contains growth inhibitory factors such as semaphorins, nephrins, tenascin and
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chondroitin sulfate proteoglycans [61, 69, 70]. Myelin-associated inhibitors found in
the glial scar, such as Nogo-66, myelin-associated glycoprotein, and oligodendroctye-
associated glycoprotein, have been shown to interact with the Nogo receptor (Ngr) to
inhibit neurite outgrowth [71]. In contrast, extracellular matrix component molecules
such as laminin have been found to promote regeneration [51]. Although the CNS
contains microglia, they do not aid in debris clearance to the extent of Schwann cells,
which attract macrophages to enhance clearance, as well as produce neurotrophic and
neurotropic factors to aid in regeneration [55]. The availability of a model that allows
for the study of CNS regeneration and determines the e↵ects of these factors within
an injury platform would be valuable.
2.4 Microfluidic Devices for Studying Nerve
Injury and Regeneration
Traumatic injuries, both in CNS and PNS, can lead to irreversible damage result-
ing in permanent loss of function. Studying the complex dynamics involved in these
processes may elucidate the biological mechanisms of nerve regeneration and degener-
ation, potentially leading to the development of new strategies and therapies for nerve
regeneration and recovery. In vivo animal models of trauma have permitted the study
of a multitude of complex variables and permit the analysis of behavioural outcome,
enabling monitoring of prognosis and determination of functional outcome to various
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treatment strategies. These in vivo animal experiments include models of instant ro-
tational injury, impact acceleration injury, lateral fluid percussion injury, controlled
cortical impact, spinal cord compression and contusion, nerve stretch, and complete
nerve transection, as previously reviewed [72,73]. These models have provided much
insight, but they are highly complex, containing multiple parameters, have potentially
low reproducibility, and are time consuming and labor-intensive. More importantly,
they do not allow for monitoring axonal regeneration in real-time, or enable study
at the reductionist single cell level necessary for determining precise mechanisms. In
contrast, as an alternative parallel experimental system, in vitro models allow the
study of biochemical pathways, gene expression levels, and phenotypic changes at the
level of a single axon, which are extremely relevant in the study of traumatic axonal
injuries.
Microfabrication technologies enable the development of powerful platforms to
grow and manipulate neurons and in order to model and study axon injuries. These
LOC devices can be made using modified semiconductor fabrication technologies, in-
cluding photolithography, etching, and deposition methods, in order to construct mi-
croscopic structures in glass, silicon or polymeric materials such as poly(dimethylsiloxane)
(PDMS). These platforms can play a role in the development of novel and innovative
surgical and repair strategies for damaged PNS axons. Conventional mass produced
metal surgical instruments are a↵ordable, but are not durable and degrade quickly,
while instruments made of diamond and ceramics are durable but are expensive.
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MEMS-based technology can enable development of unprecedented Si probes and
blades with enhanced performance characteristics and cost of production. For cell
culture, LOC devices provide perfusion to cells or enable probing of cells and cell
compartments with chemical reagents. Microfluidic platforms further facilitate study
at the single cell resolution of axons isolated from soma through compartmentaliza-
tion. Composite microfluidic platforms, with compartments for neurons and means to
carry out highly parallel experiments constitute high-throughput LOC devices. Such
devices enable precise control over cellular microenvironments, require small volumes
of reagents, and have potential for automation and multiplexing [29,74]. Microfluidic
systems have been broadly employed for neuron cell culture, neuron manipulation,
neural stem cell di↵erentiation, neuropharmacology, neuroelectrophysiology and neu-
ron biosensors [28, 75].
The most well-known microfluidic devices for neuronal study are compartmen-
talized LOC systems fabricated through PDMS soft lithography. There are several
properties that make PDMS an excellent choice for biological studies. As a material,
PDMS is inexpensive, flexible, and easily fabricated and bonded to other materials. It
is also biologically inert, nontoxic to cells, impermeable to water, permeable to gases,
and optically transparent down to 230 nm, facilitating microscopy [76]. Typically,
a master wafer is created using standard photolithography techniques and replicas
created from the mold using PDMS soft lithography [5]. Fabrication of these types of
devices has been covered elsewhere, and will not be the focus of this review [5,25,77].
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LOC platforms facilitating compartmentalization and thus separation of axons from
cell body allows precise tailoring and manipulation of the microenvironment of ax-
ons, distinct from the cell body, as is the case in many in vivo situations. Compart-
mentalization enables more in depth studies of myelination, neurite outgrowth, drug
screening and protection, signalling, as well as the study of networks ranging from
cellular to organ levels in organotypic cultures [5, 26, 78].
Microfluidic platforms are highly compatible with incorporation of di↵erent injury
modalities. Incorporation of an injury platform within a microfluidic culture system
would allow for better determination of axon-specific mechanisms in degeneration
and regeneration by allowing for independent manipulation of axon and cell body.
In addition, locations of injuries respective to cell bodies can be generalized within a
range for arrays of axons. Microfluidic platforms can be broadly classified as devices
that model chemical and physical injury, and devices that model the regeneration
environment. Here we provide an overview of exemplary injury devices.
2.4.1 Microfluidic Chemical Injury Devices
The simplest microfluidic injury devices provide chemical injury. Traumatic in-
juries to axons of CNS and PNS can be induced by chemicals such as chemothera-
peutics, neurotransmitters in excess (excitotoxicity), and detergents [8, 79, 80]. One
of the first and most cited microfluidic LOC device designed to study neurons in their
various compartment structures (soma, axon, dendrites) was the device created by
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Jeons group [5]. Fluidic isolation of axonal chamber from somal chamber is achieved
through microliter level volume di↵erences between the two chambers. Microchan-
nels between the chambers provide high fluidic resistance that leads to a small but
sustained flow that counteracts di↵usion. This device can be seen in Figure 2.3. Po-
tential neurotoxins can be localized precisely in the axonal compartment. Several
studies have utilized this type of device and its derivatives for examining axon in-
jury and regeneration [6,29,32,81]. These types of devices also include the ability to
direct sites of neuronal attachment and neurite outgrowth through micropatterning
techniques. Hosmane et al. created a multiplexed circular version of the platform
which utilized centrifugation to enhance axonal throughput through microchannels,
and demonstrated increased microglial accumulation to aid in debris clearance near
the site of injured CNS axons seen in Figure 2.4 [82]. Peyrin et al. developed a
three compartment microfluidic device to study simultaneous axonal degeneration
and death mechanisms of CNS axons subject to axotomy with precise spatiotempo-
ral control [79]. The injury was induced by a brief and isolated flux of detergent
in the central compartment. In their proof of concept for the device, they observed
rapid Wallerian-like degeneration in the distal axons subject to axotomy, consistent
with in vivo axotomy. Li et al. developed an integrated microfulidic platform to
chemically induce axonal injury and study the recovery and regeneration of axon ei-
ther in co-culture with glial cells in controllable chamber using valves or treatment
with monosialoganglioside, a drug aiding neuronal regeneration [80]. Their results
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Figure 2.3: A microfluidic compartment device (a) with volume di↵erences between
the two chambers (b) to maintain isolation across microchannels. Isolation was
demonstrated (c) by localization of texas red and (d) radioactive S35methionine (re-
produced with permission from [6]).
indicated that axons were more resistant to injury upon localized application of acry-
lamide compared to soma, and that axons had self-destruct programs di↵erent from
soma, where injury to the soma caused secondary axon collapse.
2.4.2 Microfluidic Physical Injury Devices
Physical modes include employing aspiration, physical cutting, laser ablation tech-
niques, valve based compression of axons [83–86]. Microfluidic platforms have been
utilized as valuable tools to study axon regeneration in vivo. Many model organ-
isms such as Aplysia californica, Caenorhabditis elegans, Drosophila and zebrafish
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Figure 2.4: A circular microfluidic platform demonstrating (a) enhanced axonal
throughput through spinning, (b) multiplexing capacity, and (c) utilization of stencils
to localize microglia (reproduced from [71] with permission from the Royal Society of
Chemistry).
have been used for in vivo neuron injury and regeneration studies [80, 83–85, 87–94].
C.elegans in particular provides an interesting paradigm for studying nerve injury and
regeneration as its genome has been completely sequenced, and in vivo axotomy for
the organism is feasible. The critical step of immobilizing the worm and subjecting
it to axotomy has conventionally been done through the use of glue and anesthetics.
These methods can either have unknown toxic e↵ects that are di cult to evaluate
or are labor intensive and of low throughput. Microfluidic platforms can provide a
clever alternative to these techniques. The immobilization can be achieved in several
ways like anesthetizing, cooling, or trapping the worm using deflectable valves [26,95].
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Choksi has developed microfluidic platforms to immobilize single worms on either a
short term or long term basis to characterize their on-chip behavior [84]. The immo-
bilization is achieved in one of the two approaches; either CO
2
is utilized to change
the micro-environment and cease the worms movement in a long term fashion, or
a deformable membrane is utilized to mechanically restrict the worm. A behavior
module revitalizes the worm after immobilization through mechanical stimulation,
consisting of a saw shaped microchannel that forces the worm to move in a sinusoidal
pattern so that its locomotion can be analyzed.
While studying nervous system injury in model organisms such as C. elegans, an
enormous volume of screening studies often needs to be done involving massive image
acquisition and processing, data acquisition and interpretation. MEMS platforms can
be integrated with imaging to increase the performance and throughput of these stud-
ies. The potential for automation is high on these platforms because of their small
size and scale. A robust and high throughput performance can be achieved on these
platforms [96]. Chung designed and developed an automated, integrated microflu-
idic system to perform high-throughput microsurgery [85]. This device is capable of
processing multiple worms in parallel without increase in control complexity. The
device can be used to simultaneously load worms in one set of channels and perform
imaging and laser ablation in the other set. Guo developed a high throughput mi-
crofluidic platform for in vivo nerve regeneration studies that enables precise focusing
and nanosurgery of trapped worms and feeding for recovery of the operated worms
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in two di↵erent modules [83]. The device also incorporates an adjustable trap for im-
mobilization of worms at various developmental stages. Highly specific laser ablation
techniques can be used to injure the worms once they are steadily immobilized. Using
this chip, they observed faster than expected rates of axonal regeneration, and that
distal fragments of the severed C. elegans axon regrow in the absence of anesthetics.
Based on the frequency or the repetition rate of laser, the gaps created in the axotomy
vary. With high frequency lasers 2-5 m gaps are created where as low frequency lasers
result in precise 1-2 m gaps [87,97]. Other physical modes of injury to axons involve
needles to transect individual axons, fluid percussion, and microelectrodes [79].
The mechanical and cellular response to injury can be quite complex, but study
of such stimuli can be simplified by using controlled cellular injury in vitro models.
These models include several advantages over in vivo animal models including the
ability to monitor real-time acute injury responses [61]. Existing in vitro injury
models have subjected neural cultures or explants to the forces experienced during
traumatic CNS injury, and include stretchable deformable membranes, two-photon
laser ablation, and hydrodynamic shear based axotomy through microfluidic channels
[79, 98–100]. Recent advances in culturing neurons within hydrogels has allowed for
the development of three dimensional cultures that allow for bulk deformation [101].
Mechanotransduction is the study of cellular adaptation to internal and exter-
nal mechanical stress. Cells elicit a downstream biochemical signal in response to
variations in forces acting on a cell. Several tools have been developed to study the
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combinatorial interplay between mechanical properties and force induced biochemical
changes in cells [102]. The mechanotransduction of CNS and PNS injuries provide
powerful insights for development of treatment strategies, and accordingly, several in
vitro platforms have been developed to study mechanotransduction in injury. Stretch
induced injury is one of the many modes of mechanotransduction and physical injury
observed in vivo during traumatic insult to axons of CNS and PNS. Several groups
have modelled and studied these injuries in vitro. A stretch-induced injury model of
rat cortical astrocytes was developed by culturing the cells on a deformable mem-
brane which was subjected to deformation by a positive rapid pressure [103]. The
astrocytes were grown in tissue culture wells on flexible silastic bottoms to which
a pressure was applied that stretched the membrane and in turn the astrocytes in
order to study the morphologic, physiologic and biochemical consequences of stretch-
induced injury. The system enabled the study of the extent and degree of injury with
precise control over membrane deformation by varying the amplitude and duration
of pressure. Cell injury was demonstrated to be proportional to the degree of silas-
tic membrane deformation, with increasing stretch causing mitochondrial swelling,
disruption of glial filaments, and vacuolization. This is one of the earliest in vitro
attempts to study injuries in cells derived from the brain. With the advancement in
MEMS, novel platforms could be developed to study the role of mechanotransduction.
in traumatic axonal injuries. The forced being applied on an axon determines its fate
of degeneration, regeneration, or stalling in place.
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In a more recent study, Hosmane developed a valve-based axon injury platform
that enabled compression of CNS axons at the micron-scale, seen in Figure 2.5 [86].
The valves controlled push-down pads that descended upon application of compressed
gas. The pressure of the gas was modulated in order to create di↵erent levels of injury.
Increased pressures, more likely to cause axotomy, were found to promote subsequent
axonal regrowth. In another example, Smith applied continuous mechanical tension
to axons, and achieved a sustained, rapid growth [104]. The device physically split
integrated neuronal cultures into two halves and separated the halves progressively
further apart using a microstepper motor system. In doing so they achieved a growth
rate of 1mm/day. Transecting axons to induce axonal injury by laser ablation, as
discussed previously in whole organisms, is another physical injury technique [81,97,
100, 105]. Kim et al. developed a neuro-optial microfluidic platform that integrates
a microfluidic chip, femtosecond laser for axotomy and mini-incubator to maintain
a sterile and appropriate microenvironment for long term monitoring of events post-
injury [100]. An example of the laser ablation achieved within these devices can be
seen in Figure 2.6.
These injury devices also contained soluble and surface bound inhibitors within the
injury compartment in order to better mimic the regeneration environment in vivo.
Sretavan et al. developed a microdevice to assist the axon regeneration after injury
[21]. This device included the development of a silicon nitride knife with ultra-sharp
knife edge with a 20 nm radius of curvature produced utilizing MEMS technology.
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Figure 2.5: (a) A valve-based injury platform with images detailing the (i) cell layer
process flow and (ii) control layer process flow, followed by (iii) top down and (iv)
cross-section images to visualize control layer (red) versus cell layer (blue). (b) Be-
low, axon compression, degeneration, and regrowth are monitored real-time within
a representative device, with degeneration apparent at an image from 30 minutes,
and the start of regrowth apparent in the 1 hour and 30 minute image (reproduced
from [86] with permission from the Royal Society of Chemistry).
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Figure 2.6: (a) Schematic of the laser-based injury device can be seen, along with (b)
representative images of DRG growth through microchannels, and a higher magnifi-
cation of the same. (c) A representative axon bundle cut with a femtosecond laser
demonstrates high thermal confinement of the site of injury. Axons can be seen (d)
entering and (e) traveling through microchannels in higher resolution images (adapted
from [100] with permission from the Royal Society of Chemistry).
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This knife was used for cutting regions of damaged axons individually. These damaged
segments were replaced with healthy donor axon segments through dielectrophoresis
(DEP), which was used to manipulate and line up the donor axon segments in the
region of interest. The axon membranes of the segments were successfully electrofused.
2.4.3 Microfluidic Devices Recreating
Regeneration Environments
One of the major obstacles for regeneration is the distance or gap between the
proximal extending axon and the distal stump. In bridging this gap, axons have to
circumvent the non-permissive substrates for neurite growth, while certain growth
factors and other transient molecules may aid positive guidance. Recent studies have
showed that targeting a specific group of extracellular inhibitory factors in itself was
insu cient to promote long-distance regeneration of CNS axons. Hur et. al aimed
to promote regeneration by directly targeting the growth cone through pharmaco-
logical inhibition or genetic silencing of nonmuscle myosin II (NMII) [78]. As part
of this study, the axonal compartment was coated with inhibitory chondroitin sul-
phate proteoglycans, and the e↵ect of applying blebbistatin, a specific inhibitor of
NMII ATPase activity, was examined. As can be seen in Figure 2.7, application of
blebbistatin allows axons to overcome inhibitory cues. The inhibition of NMII causes
reorganization of microtubules and actin in the growth cone in a way that allows for
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Figure 2.7: Inhibition of NM II allows axons to overcome inhibitory substrates in the
axonal compartment of a microfluidic device. (a) Schematic of the two-compartment
chamber is given. (b,c) Representative images of DRG neurons facing the inhibitory
chamber demonstrate inability to breach the border. (d,e) Blebbistatin was locally
applied to the axonal side, demonstrating an ability to overcome inhibitory cues
(reproduced with permission [78]).
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rapid axon extension, both over permissive and inhibitory substrates.
Over the time course post-injury, chemical gradients of several neurotrophic fac-
tors are established; these gradients may significantly influence the growth dynamics
of axons post-injury and may even play a role in determining the fate of axons to-
wards regeneration or degeneration. Establishing gradients in neuronal culture may
deliver powerful insights about regrowth dynamics. MEMS platforms, due to their
operating dimensions and small scale, make it feasible to establish stable gradients
over time. For example, gradients can be established on these platforms by exploiting
the surface tension di↵erences between two ports connected by a microchannel. This
same principle is applied to develop and demonstrate a passive pump in microfluidic
devices [106].
LOC devices that mimic the repulsive or attractive chemical cues present in the
regeneration environment provide insight into how to best guide regrowing axons
towards appropriate targets. In the event of injury, neurites need to perform the
non-trivial tasks of reorganizing and re-establishing existing connections. Kothapalli
et. al developed a novel microfluidic device to study neurite guidance under the
influence of chemo-gradients [107]. The neurons were cultured in micro channels on
a physiological 3D environment of collagen type-I, and gradients were established of
chemo-attractants such as Netrin-1 and chemo repellents such as Slit-2. The gradients
developed were stable up to 48 hours. This time frame allowed for the qualitative and
quantitative study of neurite turning, providing valuable insight into the development,
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maintenance and reorganization of complex neural networks. The ability to monitor
and guide regrowing axons can enhance our e↵orts in promoting functional recovery.
2.5 Conclusions
Nerve injury is a widely observed, but di cult to study phenomenon, particularly
in vivo. The current standard treatment for peripheral nerve injury, such as end-to-
end surgical reconnection, or reconnection with an autologous nerve graft, are also
highly limited. While in the periphery nerve regeneration occurs, functional recovery
may not. In the central nervous system, the outlook is starker, as no treatments
are currently available. A more complete understanding of the neurobiology of nerve
injury and regeneration in both of these systems may improve surgical or biomaterial
or sca↵old-based repair outcomes and functional recovery. Therefore, in vitro meth-
ods are of interest so as to very precisely and microscopically observe nerve injury
and develop and test di↵erent repair strategies. Continuing advances in the field of
microtechnology enable the creation of devices capable of studying regeneration at
the reductionist cellular scale, allowing for the ability to tease out mechanisms that
may be lost at the complex in vivo setting. Chemical injury can be easily achieved
within a microfluidic platform, while physical injury is accomplished through the in-
corporation of other technologies such as lasers, nanoscale ultra-sharp knives, and
valve-based compression. The post regeneration environment can also be modelled,
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through chemical modifications of the device surface or alteration of fluid flows. While
the strength of microfluidic devices are in their reductionist, highly controllable envi-
ronments, currently available microfluidic devices do not perfectly mimic the in vivo
environment, particularly as most operate at the two-dimension level and many ef-
fects may not translate from the cell level to in vivo. Large surface to volume ratios
and particularly miniscule amounts of media may lead to cell viability issues due
to evaporation and potential di culty in maintaining cell culture conditions, if not
tightly managed. The devices have promoted the formation of interdisciplinary and
collaborative research teams, but wide-scale adoption by neuroscientists, although
expected, has not yet occurred. Despite these concerns, microfluidic devices continue
to look promising for investigating axonal regeneration. A variety of LOC devices
discussed in this review point to a vibrant field where novel platform technologies
are facilitating cellular discoveries and basic research is promoting the development
of novel platform technologies. Next generation devices are expected to better mimic
the three-dimensional in vivo regeneration environment, as well as incorporate other
advances in other fields such as optogenetics and biosensors, in order to extend fun-
damental findings from cellular studies and take a step closer to realizing clinical
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This chapter has been published as a paper in Experimental Neurology [8] and
reprinted in accordance with the guidelines of the journal.
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3.1 Abstract
Chemotherapy induced peripheral neuropathy is a common and dose-limiting side
e↵ect of anticancer drugs. Studies aimed at understanding the underlying mechanism
of neurotoxicity of chemotherapeutic drugs have been hampered by lack of suitable
culture systems that can di↵erentiate between neuronal cell body, axon or associated
glial cells. Here, we have developed an in vitro compartmentalized microfluidic cul-
ture system to examine the site of toxicity of chemotherapeutic drugs. To test the
culture platform, we used paclitaxel, a widely used anticancer drug for breast cancer,
because it causes sensory polyneuropathy in a large proportion of patients and there
is no e↵ective treatment. In previous in vitro studies, paclitaxel induced distal axonal
degeneration but it was unclear if this was due to direct toxicity on the axon or a con-
sequence of toxicity on the neuronal cell body. Using microfluidic channels that allow
compartmentalized culturing of neurons and axons, we demonstrate that the axons
are much more susceptible to toxic e↵ects of paclitaxel. When paclitaxel was applied
to the axonal side, there was clear degeneration of axons; but when paclitaxel was
applied to the soma side, there was no change in axon length. Furthermore, we show
that recombinant human erythropoietin, which had been shown to be neuroprotective
against paclitaxel neurotoxicity, provides neuroprotection whether it is applied to the
cell body or the axons directly. This observation has implications for development
of neuroprotective drugs for chemotherapy induced peripheral neuropathies as dor-
sal root ganglia do not possess bloodnerve-barrier, eliminating one of the cardinal
50
CHAPTER 3. CHEMICAL INJURY
requirements of drug development for the nervous system. This compartmentalized
microfluidic culture system can be used for studies aimed at understanding axon
degeneration, neuroprotection and development of the nervous system.
3.2 Introduction
Peripheral neuropathy is a relatively common disease that a↵ects at least 2.4%
of the population in the US [108]. Prevalence increases with aging population and
reaches as high as 26% of people older than 65 [109]. Typical symptoms of pe-
ripheral neuropathy reflect sensory, motor, or autonomic nerve fiber dysfunction. In
particular, sensory symptoms include paresthesias, some of which are painful, sen-
sory loss and numbness. In most polyneuropathies, these symptoms begin distally
in extremities and progress proximally [110, 111]. The pathologic changes in most of
these polyneuropathies are those of a distal to proximal axonal degeneration, which
have been referred to as dying-back neuropathies [112]. Currently there are no ef-
fective therapies aimed at the underlying mechanism of axonal degeneration, except
for inflammatory neuropathies characterized by infiltration of peripheral nerves with
lymphocytes and macrophages [113].
Paclitaxel, a diterpene alkaloid drug, is a commonly used chemo-therapeutic agent
against breast, lung and ovarian cancer. One of the major dose-limiting side e↵ects is
distal axonal, mainly sensory, polyneuropathy [114,115]. The symptoms of paclitaxel-
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induced neuropathy are tingling, numbness, loss of balance and burning pain. The
mechanisms of neurotoxicity of paclitaxel are largely unknown and e↵ective treat-
ments for axonal neuropathy caused by paclitaxel are currently not available. Pacli-
taxel binds to beta-tubulin and stabilizes its polymerization. This leads to disruption
of the mitotic spindle and arrest of cell division [116,117]. It has been suggested that
paclitaxel may lead to an increase and altered distribution of detyrosinated tubulin,
a marker for stable microtubules [118]. In addition to these in vitro studies, animal
models of paclitaxel neuropathy have been developed in rodents [115, 119–123], but
the underlying mechanism of distal axonal degeneration induced by paclitaxel remains
to be determined.
Although multiple in vitro models of peripheral neuropathies exist only two groups
have attempted to use compartmentalized culture systems to ask whether axonal
degeneration is due to local axonal disturbances or a consequence of derangement
in the neuronal cell body [120, 121, 124]. These groups used Campenot chambers
that consist of a Teflon divider attached to collagen-coated Petri dish with silicone
grease [4]. Campenot chambers require great skill, as leakage between chambers is
a common problem, limiting e ciency and reproducibility. Chamber systems, other
than Campenot chambers, have been developed to isolate hippocampal [125] and
motor axons [126] from soma using thin coverslips. However, these had similar prob-
lems as the Campenot chambers, leakage between chambers being the most common
one. In contrast, advances in microtechnology and biomaterials have led to numerous
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approaches that precisely control the positioning of cells on substrates [127–130]. Pre-
senting cells with controlled topographical and chemical cues have allowed us to under-
stand a great deal about how cells respond to their local microenvironments [131–134].
Microfabrication technology, utilizing photolithography, micro-contact printing, and
microfluidics, is used to construct chambers in which precise in vitro cellular pattern-
ing is achieved. Such microfabrication techniques have been used to create chemical
and biochemical analysis platforms [128,135,136].
In this study, we aim to help elucidate the underlying mechanism of paclitaxel-
induced axonal degeneration through the use of microfluidic platforms that allow us
to physically and fluidically isolate cellular compartments, as well as to gauge the
protective role of recombinant human erythropoietin. Probing di↵erent cellular com-
partments allows us to determine whether the site of action is on the cell body or
axonal side. Since most polyneuropathies are dying- back neuropathies, we sought to
determine if paclitaxel caused the most degeneration when applied to the distal axon
as compared to the cell body. Erythropoietin is a glycoprotein hormone that has
e↵ects on multiple organs and tissues. We have previously shown that this hormone
is involved in an endogenous neuroprotective pathway through Schwann cell-derived
erythropoietin [137], and demonstrated this e↵ect both in vitro and in vivo [120,121].
The mechanism of action is not precisely known, and thus we wish to determine if
there is a di↵erential e↵ect based on application of the hormone to cell body or axonal
side for its implications in the treatment for polyneuropathies. We used microfabrica-
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tion techniques to develop a novel microfluidic platform to e ciently load and isolate
neuronal cell bodies from axons with independent manipulation of the neuronal cell
body and axons. Using this platform we demonstrate that the chemotherapeutic
drug paclitaxel is toxic at clinically relevant pharmacological doses when applied to
the axons but not to neuronal cell bodies. Furthermore, we show that recombinant
human erythropoietin can protect against this axonal toxicity even when it is applied
to the neuronal cell body compartment.
3.3 Materials and Methods
3.3.1 Microfabricated Chamber Preparation
A two-step photolithographic process was utilized to create the master mold as
depicted in the schematic in Figure 3.1. Silicon wafers (University Wafer, MA) were
coated with SU-8 2002 (Microchem; MA), spun, and soft baked using parameters
specified by the manu- facturer to yield a resist thickness of 2.5 m. An array of
microchannels (Figure 3.1A), each with dimensions: width = 10 m, length = 500
m, were defined by UV light exposure through a high resolution DPI transparency
(Cad/Art, OR). The exposed substrate was once again baked, to enhance polymer
cross-linking post exposure, and developed as stated in the resist technical sheet to
fully define the microchannels. The process was immediately repeated with SU-8 3050
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Figure 3.1: The device mold was constructed using standard SU-8 photolithography.
(a) The first resist layer (h = 2.5 µm) defined an array of microchannels while the (b)
subsequent step (h = 150 µm) defined larger fluidic ports and reservoirs (not drawn
to scale). (c) Silicone rubber was then poured and cured over the mold to yield the
final device structure. (not drawn to scale). A picture of the final device can be seen
in (d).
(Microchem; MA) to define the fluidic reservoirs with dimensions: width = 3 mm,
length = 13 mm (Figure 3.1B). The master mold was then treated with trichlorosi-
lane (United Chemical Technologies; PA) for 30 min to create a nonstick surface for
subsequent processing. Standard soft lithography was performed using Sylgard 184
polydimethylsiloxane (PDMS) (Dow Corning, MI) as described previously [138]. Af-
ter curing, the PDMS was carefully removed from the master and access ports were
created using a suite of dermal biopsy punch tools (3-6 mm) (Huot Instruments, WI)
(Figure 3.1C).
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3.3.2 Cell Preparation
All experiments involving animals were conducted according to protocols approved
by the Animal Care and Use Committee of the Johns Hopkins University School of
Medicine. Unless otherwise noted tissue culture supplies were obtained from Invit-
rogen (Carlsbed, CA). Dorsal root ganglia (DRG) neuronal cultures were prepared
as previously described [139]. Briefly, DRGs were dissected from decapitated embry-
onic age day 15 rats. Once obtained, cells were enzymatically dissociated with 0.25%
Trypsin in L15 medium and then suspended in media. The DRGs were maintained
in Neurobasal medium containing 10% fetal bovine serum, 20% glucose, 1% peni-
cillin/streptomycin, B-27 supplement, 2 M L-glutamine, and 10 ng/ml glial derived
nerve growth factor (GDNF). Two days after seeding cells, neurobasal media con-
taining 10 µM of cytosine arabinoside was added to the cultures in order to decrease
the amount of glial cells. Paclitaxel (Sigma-Aldrich) was dissolved in cremophor
EL/ethanol (50/50 v/v) for a stock concentration of 5.0 mg/ml and stored at  20 C.
Recombinant human erythropoietin (EPO) was obtained from R&D Systems (Min-
neapolis, MN) and dissolved in phosphate bu↵ered saline (PBS) and stored at 20 C.
DRG neurons were loaded into the soma side of devices and grown for 5-7 days
to allow axons su cient time to grow through channels and into the axonal side at a
su cient length. Paclitaxel was diluted in neurobasal media to achieve a concentra-
tion of 25 ng/mL and applied to either the neuronal cell body or axonal side. EPO
was diluted in culture medium and applied to neuronal cell body or axonal side. Cells
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were subsequently stained with calcein AM (green) at a concentration of 2.5 µM for
1 h and imaged using a fluorescent microscope.
3.4 Results
In order to identify the susceptibility of axons and cell bodies to paclitaxel, we
added 25 ng/mL of paclitaxel to either axon or cell body chambers and continued
to culture the DRGs for another 24 h. Once images of the fluorescently labeled cells
and axons were captured, we used ImageJ to calculate axon lengths and calculated
percent change in axon length compared to 24 h before taxol exposure. In Figure 3.2,
we see images of the DRGs before and after paclitaxel exposure, all taken at the same
magnification. In these images, we see the axons exiting channels on the left side
and going into the axonal compartment on the right. Figure 3.2 A and B show axons
before and after paclitaxel was administered to the axonal compartment, respectively.
We can see a noticeable di↵erence in the axon length, as well as morphology. Figure
3.2 C and D show axons before and after paclitaxel was applied to the neuronal cell
body compartment. There is not as noticeable a di↵erence in the axon morphology
or length. From these images we see that paclitaxel caused axonal degeneration when
applied to the axonal compartment, but not when applied only to the cell body
compartment.
Studies on the neuroprotective e↵ect of EPO were performed with concurrent
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Figure 3.2: Paclitaxel induced local axonal degeneration. Axonal degeneration upon
axonal administration of paclitaxel for 24 h is seen only with local axonal application
(A = before paclitaxel; B = after paclitaxel) but not with paclitaxel application to
the neuronal cell body chamber (C = before paclitaxel; D = after paclitaxel).
administration of paclitaxel, which was applied to either the neuronal cell body or
axonal side. In order to study the e↵ect of EPO on di↵erent cellular compartments,
we also applied the hormone to either the neuronal cell body or axonal side of the
chambers. Figure 3.3 A and B show axons before and after administration of EPO and
paclitaxel to the axonal side of the chamber, respectively. From these images we see
that there is not a large di↵erence in axon morphology or length, demonstrating the
neuroprotective e↵ect of EPO as it seems to prevent axon degeneration. This e↵ect
was also seen when EPO was applied to the neuronal cell body compartment when
paclitaxel was applied to the axonal compartment. Quantification of the results can
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be seen in Figure 3.4. Axon degeneration was defined as the change in axon length
over the total axon length expressed as a percentage. When only paclitaxel was
applied to the axonal side, we saw a 28.6+11.2% decrease in the length of axons,
compared to a control in which no paclitaxel was added that showed a 0.42 + 0.25%
increase in axon length. Paclitaxel applied in combination with EPO on the axon
side showed a 1.02 + 0.42% decrease in axon length, which was more comparable to
the control than to the paclitaxel-induced degeneration condition. When paclitaxel
was applied on the axon side while EPO was applied to the soma side, we saw a 1.34
+ 0.59% decrease in axon length, again demonstrating a neuroprotective e↵ect.
Figure 3.3: Neuroprotective e↵ect of EPO. A protective e↵ect of EPO is observed
24 h after concurrent administration with paclitaxel to the axon compartment (A =
before paclitaxel+EPO; B = after paclitaxel+EPO).
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Figure 3.4: Quantification of axon degeneration with paclitaxel administration and
axon protection by EPO. Axon lengths were measured on the axonal chamber before
and 24 h after application of paclitaxel with or without EPO and expressed as a
percent change from baseline. Average N=10 for conditions. (⇤ denotes p < 0.05)
3.5 Discussion
Paclitaxel-induced sensory neuropathy is a frequent and disabling side e↵ect, and
can potentially lead to the discontinuation of chemotherapy. The microfluidic plat-
form used in this study allowed us to better clarify the mechanism for paclitaxel-
induced degenera- tion. The device used in this study does not allow mixture of
culture fluids between chambers and provide glass substrate for better optical mi-
croscopy compared to Campenot chambers and its derivatives. Furthermore, the
microfluidic platform is based on the PDMS, which has excellent gas exchange prop-
erties. Recently, Taylor and colleagues developed a microfluidic chamber for the
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compart-mentalized culture of neurons [5]. However, these chambers had di culties
in cell loading close to microchannels and low number of axons per microchannel.
In contrast, the microfluidic platforms used in this study are simple to load with
su ciently high-density cells and corresponding higher amounts of axons inside mi-
crochannels. There was ample segregation of neuronal cell bodies and axons.
In a previous study, we had shown that paclitaxel can cause axonal degeneration
but not neuronal death at pharmacological doses used in chemotherapy [120, 121].
What we did not know at that time was whether this axon degeneration was due to
local toxicity of paclitaxel in the axon or a consequence of disruption of cellular events
within the neuronal cell body. This study clearly shows that paclitaxel causes axon
degeneration through local mechanisms, but that this local toxicity can be controlled
by intracellular events induced at the cell body as shown by the EPO data. We
know that paclitaxel induces an increase in detyrosinated tubulin, thereby leading
to cold-stable microtubule assembly within the axons [116, 120, 121, 140]. How this
leads to axonal degeneration is still unknown, although prevailing hypothesis is that
it interferes with axonal transport depriving distal axons of their vital nutrients and
cellular substrates. Rapid degeneration seen in previous studies and in our culture
system suggests perhaps a di↵erent mechanism. A curious observation we had in our
axonal chambers was presence of axonal blebbing even in the most proximal segments
of axons in paclitaxel-treated axonal chambers (data not shown). Axonal blebbing is
often regarded as a prelude to axonal degeneration but it can be a reversible process
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[141]. Local axonal activation of protein degradation pathways, such as caspases or
calpains could lead to axonal blebbing and eventual degeneration.
We used the microfluidic chamber platform to examine the site of axon protective
action of EPO, expecting that local axonal application of EPO would prevent axonal
degeneration induced by paclitaxel. We, however, found that EPO was able to prevent
paclitaxel-axonal degeneration even when it was applied to the cell body, away from
the axon and paclitaxel. Although we do not know the mechanism of this axon
protection, it is possible that EPO–induced changes in intracellular signaling events
are transported down the axon using fast axonal transport and block the toxicity of
paclitaxel. We do not know if this type of potential mechanism of neuroprotection
may apply to other axon protective therapies, but if it does, then the implications for
drug development for peripheral neuropathies are immense. One of the limitations
of developing therapies for nervous system indications is that axons and neurons are
behind a blood-brain/nerve-barrier. This requires that the drugs be able to cross the
blood-brain–barrier. However, there are exceptions to this rule and the blood-brain–
barrier within the dorsal root ganglia is very leaky. If axon protection can be achieved
by action of a drug on the neuronal cell body, even for toxins that cause local axonal
degeneration, there would be a less stringent requirement for the drug to cross the
blood-brain–barrier. Future studies will help us define if this is a general principle.
In summary, we have developed a novel microfabricated platform, composed of
a microfluidic culture system, that is robust, easy to manufacture and reliable. It
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allows separation of axons from neuronal cell bodies and independent manipulation
of each compartment. It can be used to study mechanisms of axonal degeneration,
protection against axonal degeneration and developmental events such as myelination.
Furthermore, the manufacturing process is scalable to generate templates with more
than hundred chambers that can be independently manipulated, thus allowing high-
content studies including drug screening. Through the use of this device, we have
demonstrated that paclitaxel causes degeneration of axons through local mechanisms.
We have also shown that this e↵ect can be counteracted through the administration
of EPO both at the cell body and at the axon, indicating exciting implications for




culture platform to study axonal
regeneration and localized e↵ects
of GDNF
4.1 Abstract
In this chapter, the characteristics of compartmentalized microfluidic platforforms
are further investigated and the devices are utilized in a physical axotomy model.
The regenerative e↵ects of members of the glial cell line-derived neurotrophic fac-
tor (GDNF) family of ligands (GFLs) is then explored post-axotomy. As discussed
64
CHAPTER 4. PHYSICAL INJURY
previously, microfluidic compartmentalized devices contain high fluidic resistance mi-
crochannels where hydrostatic pressure is utilized to create a small but sustained flow
to counteract any di↵usion. We examined this property further by characterizing the
di↵usion profiles of molecules in the device both theoretically and experimentally. A
fluidic height di↵erence of 2 mm was required to localize fluorescent molecules in one
side of the compartment. This height di↵erence was used to determine the di↵usion
profile of a representative growth factor used for subsequent experiments. For these
experiments, the e↵ects of members of the GFLs, specifically neublastin, neurturin,
and GDNF, were investigated in order to compare their ability to regenerate the axons
of dorsal root ganglion (DRG) neurons after in vitro axotomy within the microfluidic
chamber. The DRGs were grown in the cellular compartment and axons were allowed
su cient time to grow through a microchannel array and into a neighboring axonal
compartment where they were severed by gently scratching with either a glass pipette
or metal syringe tip. GDNF, neuturin, or neublastin were administered to the axonal
or cell body compartments to enhance axonal regeneration. GDNF was most potent
in promoting axon outgrowth after axotomy, although all explored growth factors
demonstrated some e↵ect. Application of GDNF to either cell body or axon side
was e↵ective in enhancing regeneration. To investigate this further, we performed
experiments within microfluidic cultures with concurrent application of GDNF with
a retrograde transport blocker, cytochalasin D. The initial experiments demonstrated
that GDNF applied to the axon is no longer as e↵ective, indicating the importance
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of transport to the cell body. To examine the e↵ect of GDNF at the tissue level,
we explored the application of GDNF to adult DRG explant cultures, both with and
without the presence of laminin. Results indicate the e↵ect of GDNF is strongest
during the initial days following injury and application, and that this e↵ect is most
pronounced without laminin. These factors can be considered for eventual growth
factor based treatments for the enhancement of sensory axon regeneration.
4.1.1 Chapter Organization
This chapter is organized slightly di↵erently than other chapters in this disserta-
tion. After an introductory overview, this chapter presents the characterization of
fluidic isolation in microfluidic devices, including theoretical and simulated predic-
tions followed by experimental verification. Compared to the paclitaxel experiments
in chapter 3, these experiments are longer in duration, and hence the characterization
of fluidic isolation was essential. After this section follows the growth factor experi-
ments section, including the materials, methods, and results at both the cellular and
tissue level. The discussion concludes, covering all sections.
4.2 Introduction
Compartmentalized cell culture devices have become widely used in neuroscience
studies. As discussed in Chapter 2, while the Campenot chamber is the prototypical
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device of this type, more recently, microfabricated devices have been developed to
separate neuronal cellular components with enhanced control. In particular, poly-
dimethylsilosane (PDMS) based microfluidic devices have been extensively used in
isolating axons of both CNS and PNS neurons [8,82,129]. Specifically, PDMS enables
high fidelity molding of microscale features, is biologically inert, optically transpar-
ent, and contains tunable mechanical properties. These types of devices have been
discussed in detail in Chapter 2. These devices allow for physical separation of cell
body from soma through size limitations of the microchannels, which are only large
enough to allow axons to pass through, as well as fluidically isolated both due to a
combination of the high resistance of the microchannels and an applied hydrostatic
pressure [142,143].
In this study, we sought to characterize fluidic isolation of somal and axonal com-
partments and examined the site of action of three neurotrophic factors in an in
vitro axotomy model of sensory axonal regeneration. To characterize fluidic isola-
tion, we examined and verified parameters essential to growth factor di↵usion. We
determined the di↵usion profile of growth factor within our devices to confirm small
molecule isolation through theoretical, computational, and experimental means. Once
characterized, we proceeded with the growth factor experiments. We examined three
members of the glial cell line-derived neurotrophic factor (GDNF) family of ligands
(GFLs) as they play important roles in neural development and di↵erent neurological
diseases [144–149]. These growth factors have been shown to promote survival and
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di↵erentiation of dopaminergic neurons, motor neurons and sensory neurons from
dorsal root ganglia (DRG) [150–155]. GDNF in particular has been investigated due
to its therapeutic potential. Previous studies have evaluated the role of GDNF in the
nervous system in settings of disease and traumatic injury [156–158]. In addition to
GDNF, other members include neurturin, neublastin (also known as artemin), and
persephin [159]. It has been demonstrated in both clinical trials and animal experi-
ments that GDNF enhances myelination [139,160,161]. GDNF also enhances survival
of motor neurons in models of amyotrophic lateral sclerosis [162–164], and dopamin-
ergic neurons in models of Parkinson’s disease [165, 166]. Similarly, neurturin has
been shown to increase survival of motor and dopaminergic neurons [167–169] and
neublastin was e↵ective in reducing neuropathic pain [170–172]. While GDNF has
shown great therapeutic potential, the biological site of action of GFLs in axon re-
generation is not well characterized.
Identification of biochemical mechanisms involved in axonal injury can be di cult
in a complex in vivo experimental setup. In addition, standard cell culture does not
allow for the compartmentalization of axons from neuronal cell bodies, thus making it
di cult to delineate axon-specific mechanisms. Using a microfluidic chamber system
we examined the regenerative potential of GDNF, neurturin and neublastin. From
previous demonstrations that GDNF is upregulated post-injury and has regenerative
potential, we expect GDNF and related GFLs to enhance axon outgrowth post ax-
otomy. If this e↵ect is truly primarily based on cellular versus local mechanisms at
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the site of injury, we expect the concurrent axonal application of the growth factor
with cytochalasin D, a retrograde transport blocker, to be less e↵ective than axonal
application of the growth factor alone.
Due to several environmental di↵erences in vitro versus in vivo, including the
enhanced presence of endogenous growth factors as well as the presence of more
substantial support cells and ECM components, we expect that the in vitro and in
vivo results may not be identical. In order to investigate the role of GDNF at the
tissue level, we performed experiments with adult DRG explants. Laminin is prevalent
throughout the body within ECM and is known to have axonal growth promoting
properties both in vivo and in vitro, and thus experiments were performed with
and without the presence of laminin [51, 173]. We expect the results help to further
elucidate GDNF’s role in regeneration following injury as well allow for further factors
for consideration in its potential use as a therapeutic treatment.
4.3 Characterization of Growth Factor Dif-
fusion
Prior to GFL experiments, the fluidic isolation in our microfluidic devices was
characterized by several methods due to the longer duration of experiments as com-
pared to the previous chapter. First, a theoretical profile of growth factor di↵usion
was developed incorporating the experimental parameters of our system. Next, com-
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putational simulations were performed to further characterize and visualize di↵usion
within the devices. Finally, experimental verification of small molecule isolation was
performed by observing the di↵usion of a comparably small fluorescent molecule over
time.
4.3.1 Theoretical Profile of Growth Factor Di↵u-
sion
In order to identify whether growth factors can di↵use from the axonal to cell
body compartment during the treatment of growth factors in the axonal compart-
ment, we developed models to simulate this experimental setup. The central idea
behind the compartmentalized platform is to have fluidic isolation between compart-
ments facilitated by high resistance microchannels. If the microchannels contain a
small cross-sectional area (< 30µm2), this device paradigm allows axons to grow
from one compartment into another but attenuates the di↵usion of molecules from
the compartment of lower hydrostatic pressure to the compartment of higher. In
our experiment, a small di↵erential pressure gradient was established with a higher
pressure in the axonal compartment as compared to the cell body compartment. As
a result, a low velocity retrograde flow was created in the microchannels to prevent
molecular anterograde di↵usion. We show theoretically that chemical isolations are
achieved when working with the aforementioned parameters. First we formulate the
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di↵usion-advection problem (Figure 4.1).
Figure 4.1: Formulation of the di↵usion-advection problem
The di↵usion of any molecule in a fluid medium is governed by the di↵usion-
convection equation. The first term including spatial derivatives of concentration
describes passive di↵usion while the second term including the velocity of the medium
describes active di↵usion (or the convective element):
@C
@t
= D ·r2C   !v ·rC (4.1)
Where C is the concentration at a point (x,y,z) at time t, D is the coe cient of
di↵usion,  !v indent is the velocity vector at the point (x,y,z) at time t. The pressure
and concentration gradients driving the dynamics are mainly along the groove (x-
axis) and hence, this can be approximated as a one-dimensional problem. Steady
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where u is the x-component of the velocity. Solving this with appropriate bound-










For pressure (gravity) driven flows, C
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For the purpose of simplifying calculations, media is approximated as water. In this
equation,  h is the height di↵erence of the water column at inlet and outlet that leads
to the pressure di↵erence which drives flow, ⇢ is the density and ⌘ is the viscosity of
water (saline) and a is the channel height (the most critical dimension for laminar
flow). Due to the geometry of the system,  h is limited to approximately 2 mm, and
a is limited to 2.5 µm, which is the height of the groove. The other constants used
are g=9.81 m/s2, ⌘=0.00089 m2/s, and ⇢=1000 kg/m3.
The di↵usion coe cient D is calculated indirectly from its inverse dependence on
the square root of molecular weight of the di↵using species. D
oxygen
is known to be 2
x 10-9 m2/s. The molecular weight of oxygen (M
oxygen












The smallest molecule we use is 4.5 kDa, which also thus has the highest tendency
to di↵use. It is su cient to use this molecule for our calculations as the amount of
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Table 4.1: Growth Factor Molecular Weights and Calculated Di↵usion Coe cients
Growth Factor Molecular Weight (kDa) Di↵usion Coe cient (m2/s)
Human GDNF 21 (cited from [174]) 5.5 x 10-11
Rat Neurturin 19.5 (cited from [168]) 5.7 x 10-11
Rat Neublastin 4.5 (cited from [175]) 1.2 x 10-10
GDNF di↵using to the somatic compartment will also be less than the amount of rat








Thus, there is negligible di↵usion from the axonal compartment to the somatic
compartment at steady state. Care must be taken that while performing experiments
utilizing these culture systems that the height di↵erence in the two compartments
must be achieved before adding the growth factor to the axonal compartment so that
there is always an anterograde flow preventing di↵usion of species in the retrograde
direction. This height di↵erence must be maintained throughout the experiment.
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4.3.2 Computational Simulations to Study Di↵u-
sion Patterns of Growth Factors
Simulations were done in Comsol Multiphysics (Formerly FEMLAB; Comsol Inc.,
MA), a finite element-modeling package. The geometry was simplified to study the
di↵usion pattern in only one of the microchannel grooves. Each microchannel has
a plane of symmetry passing though the middle (a plane going from floor to ceiling
all along the length halfway between the two vertical walls). Further simplification
of the geometry was performed using such symmetric considerations, so that only
half of a microchannel needed to be simulated (Figure 4.2. Simulation consisted to
meshing the architecture into a grid of smaller elements. The aspect ratio of such
finite elements was tailored to suit the aspect ratio of the microchannel, that is,
elements were longer along the length (x-axis) than along the width or height (y and
z axes respectively). The geometry was first solved for fluidic parameters such as
velocity and pressures at all points. This was done by solving the continuity and
Navier-Stokes equations for the microchannel. While all three cases were simulated
as described above, we present the results of rat neublastin (the smallest molecule
we used) di↵usion in Figure 4.3. This su ces to demonstrate the paucity of small
molecule di↵usion through a microchannel feature.
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Figure 4.2: Handling of microchannel geometry for computational simulations. Half
the microchannel groove is meshed for computational solutions of fluid dynamics and
di↵usion-convection equations.
4.3.3 Restriction of Fluorescent Molecules
In order to confirm our theoretical and simulated findings of small molecule dif-
fusion within our microfluidic chambers, experimental verification was performed. A
hydrostatic pressure was established between the compartments by establishing fluid
volumes such that the somal compartment was of lower fluidic height than the axonal
compartment. This hydrostatic pressure created a small flow to counteract di↵usion.
A 1 microliter bolus of fluorescein isothiocyanate (FITC) (Sigma, St. Louis, MO)
dye was introduced to the somal compartment and was imaged over the course of
24 hours. Empirically, a fluid height di↵erence   2 mm was su cient to prevent a
low-molecular weight compound (700 Da) from di↵using from the axonal compart-
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Figure 4.3: Computational simulation of the di↵usion profile of growth factor along
a microchannel groove. The plot demonstrates that when growth factor is applied
to the axonal side, the concentration along the groove drops to negligible amounts
within approximately 100 µm in a 500 µm channel.
ment to the somal compartment, which matches both our theoretical and simulated
conclusions. In Figure 4.4, we see that under these conditions, the di↵usion of the
dye was approximately 100 µm after 24 hours, well under the channel length and
very close to our prediction. This height di↵erence was maintained by adding 5 µL of
media to the higher volume compartment daily, allowing for localization of an applied
compound for longer periods. After verifying growth factor isolation theoretically, in
a simulation, and experimentally, we proceeded with the experiments to investigate
the e↵ect of GFLs on axonal regrowth following axotomy.
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Figure 4.4: Analyte restriction maintained for 24 hrs. Di↵usion of a small (MW 700)
fluorescent analytes were examined under high hydrostatic pressures. Microchannels
(region between dashed lines) connect compartments of unequal fluid height. Estab-
lishment of fluid heights >2 mm prevented entry of dye (solid white lines) into the
compartment of higher fluid height. Scale bar 100 µm.
4.4 Materials and Methods
4.4.1 Cell and Adult DRG preparation
All experiments involving animals were conducted according to protocols approved
by the Animal Care and Use Committee of the Johns Hopkins University School of
Medicine. Unless otherwise noted tissue culture supplies were obtained from In-
vitrogen (Carlsbed, CA). DRG neuronal cultures were prepared as previously de-
scribed [139]. Briefly, DRGs were dissected from decapitated embryonic age day
15 rats. Once obtained, cells were enzymatically dissociated with 0.25% Trypsin
in L15 medium and then suspended in media. The DRG neurons were maintained
in Neurobasal medium containing 10% fetal bovine serum, 20% glucose, 1% peni-
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cillin/streptomycin, B-27 supplement, 2 M L-glutamine, and 10 ng/ml GDNF. One
day after seeding cells, neurobasal media containing anti-mitotic agents (either 10 µM
of cytosine arabinoside, or a combination of 50 µM each of uridine and 5-fluoro-2’-
deoxyuridine) was added to the cultures in order to arrest the division of glial cells,
and then removed the following day.
DRG explants were harvested from sacrificed adult Rosa mice expressing red flu-
orescent protein in sensory neurons, ranging from spinal levels L3-L6. For a subset
of experiments, spinal origin level was noted, with a focus on L4-L6. Once explants
were obtained, they were placed in dissection medium, containing Hanks Balanced salt
solution (HBSS) (Gibco, Grand Island, NY), 4.3 mM sodium bicarbonate, 10 mM
HEPES (4-(2-Hydroxyethyl, piperazine-1-ethanesulfonic acid), 33.3 mM D-glucose,
5.8 mM magnesium sulfate, 0.03 % BSA and penicillin/streptomycin (Gibco, Grand
Island, NY). Explants were then cleaned to remove any remaining dura, and placed
on a transwell membrane filled with media underneath. Median and ulnar nerves
were obtained from wild type donor mice (C57Bl6) in the age range of p3 to p5 and
abutted next to DRG explants to allow axons to traverse through for approximately
one week to allow grafts to reinnervate.
4.4.2 Microfluidic Platform Preparation
A two-step photolithographic process was utilized to create the master mold. Sili-
con wafers (WRS Materials, San Jose, CA) were coated with SU-8 2002 (Microchem,
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Newton, MA), spun, and soft baked using parameters specified by the manufacturer
to yield a resist thickness of 2.5 µm. An array of microchannels were defined by
UV light exposure through a high resolution transparency (Cad/Art, OR). The di-
mensions of each microchannel for standard devices were: width = 10 µm, length =
500 µm. The exposed substrate was once again baked, to enhance polymer cross-
linking post exposure, and developed as stated in the resist technical sheet to fully
define the microchannels. The process was immediately repeated with SU-8 3050
(Microchem, Newton, MA) to define the fluidic reservoirs with dimensions: width
= 3 mm, length = 13 mm. The master mold was then treated with trichlorosilane
(United Chemical Technologies, Lewistown, PA) for 30 minutes to create a nonstick
surface for subsequent processing. Standard soft lithography was performed using
Sylgard 184 polydimethylsiloxane (PDMS) (Dow Corning, Midland, MI) as described
previously (Ng, et al., 2003). After curing, the PDMS was carefully removed from
the master and access ports were created using dermal biopsy punch tools (8 mm)
(Huot Instruments, Menomonee Falls, WI).
4.4.3 Collagen gel preparation
Collagen gels were prepared using a PDMS mold of roughly 50-100 microns in
thickness. The collagen gel solution was prepared by mixing Collagen I, Rat tail
(Gibco, Grand Island, NY), 7.5% sodium bicarbonate, and 10X PBS in a 8:1:1 ratio.
If laminin was used, 10 ug/ml was added to the solution. All solution preparation
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was carried out on ice and under sterile conditions. Once the mixture was vortexed,
a 20 minute wait period was observed before loading the solution into PDMS molds
in order to limit bubble formation. Gels were placed in a 37  C incubator for 2 hours
to allow adequate time for gelation of the thin films. Gels were then cut to dimension
as needed from the formed sheets and placed under transected nerves.
4.4.4 DRG Cell Experiments
DRG neurons were loaded into the soma side of devices and grown for su cient
time to allow axons to grow through channels and into the axonal compartment.
Phase contrast imaging was used for a majority of experiments. Representative axon
images and a certain subset of experiments were performed by labeling axons with
viral GFP for enhanced visibility. Axons were transected at the base of the mi-
crochannels by gently scratching the surface of the glass with either a glass pipette
or syringe tip, and neurotrophic factors were applied to axonal or neuronal cell body
compartments at a concentration of 100 ng/ml, a commonly used peak concentration
for various neurotrophic factors. For GDNF and cytochalasin D experiments, 100
ng/ml of GDNF was added to the axonal compartment concurrently with 10 nM of
cytochalasin D. Regeneration of axons was monitored by daily imaging of the axonal
side and measuring the length of longest axon coming from each microchannel. A
minimum of 10 axons per experimental condition was measured and experiments were
done in triplicates for GDNF family ligands. A minimum of 5 axons was done for
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GDNF and cytochalasin D.
4.4.5 DRG Explant Experiments
After approximately one week in culture, allowing for enough time for nerve grafts
to fully reinnervate and with a minimum of 2 days without GDNF, grafts were tran-
sected in order to mimic a nerve injury. Collagen gels with or without laminin were
placed under transected grafts in order to overcome the intrinsic directionality of tran-
swell membrane. Note that when with or without the presence of laminin is noted in
this chapter, this refers to the presence or absence of laminin within the context of the
collagen gel. GDNF was then either added or withheld after transection and during
media exchange every two days, depending on the experimental condition. Explants
were imaged under a fluorescent scope daily for 5 days. These images were stitched
and quantified using a superimposable radial grid. This grid is adjustable and starts
at a radius of 250 µm, continuing in 250 µm increments. In this way, axons that cross
over at di↵erent lengths can be binned.
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4.5 Results
4.5.1 Axotomy and Axonal Regeneration by Neu-
rotrophic Factors
In order to identify the regrowth of axotomized axons, we allowed neuronal pro-
cesses to grow into the axonal chamber and then transected axons using either a
glass pipette or metal syringe. In Figure 4.5, we see a representative device, seeded
at lower density in order for enhanced visualization of single axons, before and after
axotomy. These neurons were transfected with viral green fluorescent protein (GFP)
in order to enhance visualization. Note that while axons are cut slightly farther from
opening, there is some retraction and degeneration. For our experiments, we added
recombinant GDNF, neublastin, or neurturin to either axon or cell body compart-
ments of cultured DRG neurons for 72 hours. Multiple images of the axons were
captured using phase contrast microscopy and ImageJ (NIH; Bethesda, MD) was
used to calculate percent changes in axon lengths before and after axotomy in the
application of growth factors. In Figure 4.6, we see representative images of the DRG
axons before and after di↵erent neurotrophic factor treatments, all taken at the same
magnification. In these images, we see the axons exiting channels and traversing into
the axonal compartment on the right.
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Figure 4.5: A schematic of axotomy performed with the device is presented above. Be-
low this are representative images of axons A) before axotomy and B) after axotomy.
As summarized in Figure 4.7, all of the neurotrophic factors enhanced axonal
regeneration whether they were applied to the axonal or somal compartments but
GDNF was most potent. Furthermore, there was a slight benefit to applying GDNF
to the somal compartment. In order to verify if the enhancement e↵ect of adding
GDNF to the axonal compartment was due to local mechanisms, we carried out
experiments with concurrent application of GDNF and cytochalasin D. In Figure 4.8,
we can see that the results indicate (p < 0.05) that this enhancement is diminished
with the application of the retrograde transport blocker, indicating a need for GDNF
to be transported into the cell.
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Figure 4.6: Representative phase contrast images of regenerating axons where neu-
rotrophic factors were administered into cell body compartment. Images were taken
every 24 hours for 3 days after injury. Immediately after axotomy no di↵erence can
be seen between the conditions. Over the next 72 hours, there is very little growth
in the positive control compared to the growth factor treated conditions.
4.5.2 GDNF E↵ects at the Tissue Level
Explant cultures are more reflective of the in vivo environment than dissociated
cultures as the DRGs can be cultured with support cells such as Schwann cells and
macrophages. In order to determine if the enhancement of growth by GDNF trans-
lates to the tissue level, we cultured DRG explants with or without GDNF, and
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Figure 4.7: Axonal regeneration by GDNF, neurturin (NT) and neublastin (NB) after
the axotomy. Rate of axonal regeneration induced by the neurotrophic factors over 3
days. All tested growth factors enhance axonal outgrowth compared to the positive
control, applied to either location
with or without the presence of laminin. A representative culture immediately after
transection and 5 days later with a radial grid super imposed to demonstrate our
quantification technique can be seen in Figure 4.9. In Figure 4.10, we see axon counts
at the di↵erent radii compared. These graphs allow us to observe that there are more
axons that are at least 250 µm for both GDNF conditions and this e↵ect diminishes
over time. As we go to the larger axon lengths, particularly for axons at least 2000
µm, there are more axons for the GDNF without laminin condition, potentially due to
the initial boost. Viewed another way in Figure 4.11, we can see growth over several
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Figure 4.8: Axon regeneration with Axonal GDNF application compared with Axonal
GDNF application concurrently with cytochalasin D
days compared between our four conditions of GDNF and laminin, GDNF without
laminin, control with laminin and control minus laminin. An upward slope within our
growth curve implies increased branching since this indicates there are more axons
present at the next larger radii.
GDNF without laminin proved to have the largest amount of growth on the first
day, particularly as compared to both controls (p < 0.05). We again see that this
e↵ect is not as strong over the remaining days, until day 5, where there is again a
significant (p < 0.05) di↵erence between GDNF without laminin and control with
laminin.
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Figure 4.9: An example of a DRG culture immediately after nerve transection (inset
showing Day 0) and the same culture 5 days after transection with a template su-
perimposed to demonstrate how axonal growth was quantified. The grid is adjusted
around the nerve graft, starting at the site of transection. The template starts at an
inner radius of 250 μm from the site of injury and increases in 250 μm increments.
All axons to the right of the point of transection are axons regrowing post-injury.
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Figure 4.10: Quantification of axon counts separated by axon lengths, over 5 days in
each graph. There are significantly more axons that are at least 250 µm by Day 1
and at least 2000 µm by Day 5 for the GDNF without laminin condition particularly
as compared to either control condition.
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Figure 4.11: Quantification of axon counts at di↵erent lengths separated by day,
allowing for visualization of growth curves, with the most pronounced di↵erence on
Day 1 for GDNF without laminin
89
CHAPTER 4. PHYSICAL INJURY
4.6 Discussion
Compartmentalized microfluidic culture systems have been utilized in a variety
of neuronal studies, from examining the e↵ects of toxins and neuroprotectants on
axons versus soma, to enhancing spatial and temporal control of neurons and other
cultures, and performing axon-glia co-culture studies [6–8,82]. Several injury systems
have been incorporated within microfluidic culture devices in order to investigate
axon-specific mechanisms in injury and regeneration. These systems include simple
aspiration of the distal compartment, two-photon laser ablation, and hydrodynamic
shear based axotomy [5,79]. In the current study, through modification of the device
into an open system, we were able to transect axons simply and easily by scratching
the surface of the glass with a sharp pippette or syringe.
As compartmentalized microfluidic culture devices have become ubiquitous, ap-
propriate characterization of the di↵usion properties within the devices would not
only be beneficial but necessary. This study demonstrates a potential pitfall in de-
signing and carrying out microfluidic experiments with neuronal cultures. Unless a
proper hydrostatic pressure is maintained, there is no true fluidic separation of the
axonal and neuronal cell body compartments. Experiments studying the e↵ects of
individual local manipulations of axons and neuronal cell bodies will have to take
these observations into consideration. This is especially true for small molecular ma-
nipulations as they are more likely to di↵use through the microchannels and confound
the findings of an experiment.
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Neurotrophins have traditionally been known to play integral roles in neuronal
survival during development, but only relatively recently has their function in re-
generation been explored [53]. GDNF and its family of growth factors, neurturin,
artemin, and persephin, represent a class of novel neurotrophic factors. These growth
factors signal through a two-receptor complex consisting of rearranged during trans-
fection (RET) Trk and a glycosylphosphatidylinositol (GPI)-linked GFR-↵. The
growth factors GDNF, neurturin, artemin, and persephin preferentially bind to bind
to GFR-↵1, GFR-↵2, GFR-↵3, and GFR-↵4, respectively. GDNF has been shown to
provide neuroprotection and promote axonal regeneration, but the role of the other
family members is not as clear.
Injury to peripheral nerve reactivates its intrinsic growth capacity, and the retro-
grade transport of injury signals has been suggested to be one of the essential mecha-
nisms for regeneration [46]. The retrograde transport of GDNF has been postulated to
act as a positive injury signal for induction of regeneration [176]. The enhancement of
regeneration by GDNF within our in vitro system is consistent with previous studies.
It has previously been demonstrated that GDNF selectively promotes regeneration
of injury primed sensory neurons, both in vitro where GDNF caused enhancement of
neurite outgrowth in preconditioned DRG neurons, and in vivo where GDNF admin-
istered directly to cell bodies in lesioned spinal cord facilitated the preconditioning
e↵ect and enhanced regeneration further [177].
In our study we found that GDNF acts as a more potent inducer of regenera-
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tion than the other GDNF family growth factors we examined, and this finding is
consistent with previous studies. GDNF and its receptor GFR-1 are upregulated in
the distal denervated segment of injured nerve, suggesting that GDNF may provide
trophic support for injured peripheral neurons. No analogous upregulation of neur-
turin, persephin, and artemin or their receptors was found following injury [178].
However, it is note-worthy that we do see enhancement of regeneration at all if this
is the case.
The finding that GDNF administered to cell bodies produced better results than
GDNF administered to distal axonal compartments is interesting. A previous study
utilized compartmentalized cell culture devices to study the role of GDNF as a ret-
rograde survival factor and its ability to promote survival over long distances to cell
bodies [179]. In this study, it was found that GDNF promoted survival of DRG
neurons equally well from either distal axon or cell body application. However, this
study was not done within an injury model, and the DRG neurons were relatively
healthy, and thus the reason for this discrepancy in the potency of GDNF depending
on location of application may be due to the fact that we are using injured DRG
neurons. It is important to note that the mechanism of action of GDNF may be
di↵erent in these two systems, indicating the need to study the role of growth fac-
tors in both injury and developmental systems separately. It has been demonstrated
that GDNF and GFR-1 are retrogradely transported in peripheral axons, but these
studies were also done in relatively healthy neurons [180]. Axonal injury may have
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an impact on protein turnover and retrograde transport, and this may impair some
of the retrograde pathways for GDNF transport, making the application of GDNF
directly to the cell bodies more e↵ective. Our experiments comparing axonal GDNF
application alone and together with cytochalasin D demonstrate the important role
of retrograde transport of GDNF, as well as indicate that the enhanced regeneration
e↵ect may be cell body specific rather than at the localized axon.
Our experiments at the tissue-level were done with GDNF, which elicited the
strongest response in our cellular studies. The results demonstrate that the regen-
eration enhancement e↵ect of GDNF translates to an extent at the tissue level, but
not nearly as dramatically, as the control explant cultures regrow much better than
the control cell cultures. The fact that the enhancement e↵ect seems to be most
pronounced on Day 1 immediately following injury and application on non-laminin
coated substrates can have implications for timing of future therapy applications of
growth factors. It is important to note that after axotomy, there will be an upregula-
tion of endogenous growth factors after injury that is more pronounced in a tissue level
model as compared to cellular, and this may be why the e↵ect of exogenous GDNF is
either diminished or hidden. As GDNF is necessary for development, future studies
involving DRG explants from conditional knockout mice may elucidate GDNF’s role
further. The demonstration of a slight increase in branching is consistent with other
studies in which GDNF increases branching in di↵erent types of neurons to varying
extents [181,182].
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While laminin is widely known to promote axonal outgrowth, it is interesting to
see that the e↵ect of GDNF when there is no laminin in the collagen gel is significantly
higher than not only the control without laminin but also the control with laminin,
as this indicates that laminin alone may not be su cient to achieve optimal growth.
This finding may also have implications for future treatments for nerve injuries in
which the basal lamina is disrupted. While some studies indicate the necessity of
laminin in order to promote axonal outgrowth in the presence of growth factors in in
vitro studies, our results indicate that laminin may be a confounding factor [51].
It is also important to note that other significant data may not be as readily ap-
parent due to large error numbers associated with these DRG explant cultures. This
may be due to inherent di↵erences in not only absolute numbers of DRGs but di↵er-
ences in the distribution of subpopulations of DRGs that are responsive to GDNF.
A comparison between DRGs of the same spinal level may level the playing field to
produce lower error. Preliminary experiments were performed noting spinal level of
origin of the DRG explants, in our case L4-L6 (Lumbar level 4 to Lumbar level 6),
and without the presence of laminin. The results from these experiments indicated
that spinal level may be important in determining responsiveness to GDNF as well
as intrinsic axonal outgrowth, however, a larger scale study is needed. This is an
important area for future study, not only as it seems to be most appropriate to com-
pare DRGs at the same level, but also because a relationship between spinal level
and responsiveness to di↵erent growth factor treatments can a↵ect an eventual out-
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look for functional recovery based on corresponding level of injury. These findings
can lead to tailorable treatments for particular nerve injuries based on spinal level
origin of the nerve. In addition, performing these experiments within a tissue-level
compartmentalized platform will help tease out if there are di↵erential e↵ects based
on exposure to either solely the distal axon or cell body at the di↵erent spinal levels.
Neurotrophic factors are a promising area of research for understanding regenera-
tion. Their role in providing trophic support during development and in maintenance
of neurons has long been known, but elucidating their roles in regeneration may prove
fruitful in the development of therapies for overcoming neural degeneration and for
enhancing regeneration post-injury. Understanding axon specific or cell body spe-
cific e↵ects of growth factors and being able to distinguish between local e↵ects and
retrograde signaling will be necessary for any future therapies. Compartmentalized
microfluidic culture devices may be instrumental in these studies, but caution must
be exercised to better characterize the devices to ensure true microfluidic separation
of chambers. Progression of cellular studies to the tissue level bring us one step closer




Model of Mammalian Peripheral
Nerve Repair
This chapter has been published in the Journal of Neuroscience Methods [183] and
reprinted according to the guidelines of the journal.
5.1 Abstract
Schwann cells in the distal stump of transected nerve upregulate multiple growth
factors that support regeneration on a modality-specific basis. It is unclear, however,
which of these preferentially support motor axons. Identification of these factors
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will require a model that can isolate growth factor e↵ects to growing axons while
reproducing the complex three-dimensional structure of peripheral nerve. A two-
compartment PDMS base is topped by a collagen-coated membrane that supports
a spinal cord cross-section above one compartment. Fluorescent motoneurons in
this section reinnervate a segment of peripheral nerve that directs axons through
a watertight barrier to the second compartment, where nerve repair is performed.
Motoneurons remain healthy for several weeks. The axons they project through the
water-tight barrier survive transection and robustly cross a nerve repair to reinnervate
an additional nerve segment. Fluidic isolation of the two compartments was confirmed
with a dye leakage test, and the physiologic integrity of the system was tested by
retrograde labeling of only those motor neurons to which tracer was exposed, and
by limitation of toxin e↵ects to a single compartment. In traditional monolayer cell
culture, neuronal compartments cannot be isolated. Our previous in vitro organotypic
nerve repair model accurately modeled nerve repair, but did not allow individual
control of motoneuron and growth cone environments.This model isolates treatment
e↵ects to growing axons while reproducing the complex three-dimensional structure
of peripheral nerve. Additionally, it facilitates surgical manipulation of tissues and
high-resolution imaging.
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5.2 Introduction
The role of pathway-derived growth factors in promoting motoneuron regeneration
is poorly understood. Several growth factors are upregulated by denervated Schwann
cells in the distal nerve stump soon after injury [54]. Recently, anatomical and func-
tional subsets of these Schwann cells have been characterized by unique growth factor
profiles that have been found to support regeneration of sensory and motor axons on
a modality-specific basis [15]. Although upregulation of several growth factors di↵ers
between sensory and motor nerve, it is not clear which of these factors could be re-
sponsible for the modality-specific support of motor axon regeneration. Identification
of these factors will require a model that can both localize growth factor e↵ects to
growing axons and duplicate the complex three-dimensional architecture of peripheral
nerve.
Growth factor e↵ects on regeneration are isolated most easily in vitro. Cell culture
devices such as the Campenot chamber and its microfluidic counterparts are able to
isolate growth factor e↵ects to the growing axon. However, the three-dimensional
configuration of extracellular matrix components is especially di cult to model in
vitro [51]. As a result, currently available techniques cannot reproduce the three
dimensional structure of nerve, and thus cannot model nerve repair accurately [4, 6].
Attempts to determine the role of pathway-derived growth factors in vivo are ham-
pered by the complexity of the peri-axonal environment and by the paucity of relevant
conditional knockout mice. Growth factors are produced not only by Schwann cells,
98
CHAPTER 5. COMPARTMENTALIZED ORGANOTYPIC NERVE REPAIR
MODEL
but also by infiltrating macrophages, central glia, neurons that synapse on the regen-
erating motoneuron, and by the neuron itself. These growth factors can also have
multiple e↵ects that influence regeneration indirectly, such as promoting neuronal
survival, signaling axonal injury to the neuron, and modulating Schwann cell behav-
ior during Wallerian degeneration [184]. Clearly, there is a need for a platform that
selectively controls the growth factor environment within the three-dimensional struc-
ture of peripheral nerve. To address this need, our lab developed the first in vitro
model of adult mammalian nerve repair in an organotypic co-culture system [10].
Organotypic cultures are prepared from nervous tissue without dissociation, and thus
preserve the three-dimensional cytoarchitecture within both spinal cord and periph-
eral nerve [11, 185]. Additionally, organotypic culture of motoneurons overcomes the
di culties encountered when maintaining these cells in a monolayer environment [9].
In our previously described in vitro model of nerve repair spinal cord sections
from mice expressing yellow fluorescent protein (YFP) in their motoneurons were
co-cultured with freshly-harvested segments of peripheral nerve [10]. To reconstruct
ventral roots, these nerve segments were opposed to the ventral portion of the spinal
cord section adjacent to the motor neuron pool to promote the ingrowth of YFP-
expressing motor axons. After a week in culture, once the new ventral roots had been
reinnervated, they were transected and nerve repair was performed by opposing their
cut ends to freshly-harvested nerve grafts. As initially described, organotypic cul-
tures were grown on a Transwell c  collagen-coated insert within a 6-well plate. The
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height of the Transwell enclosure compromised our ability to perform microsurgery
on the cultured tissue and to achieve the working distances required for high resolu-
tion imaging. The Transwell construct is designed to be imaged from below; image
quality is degraded by the fluid and plastic beneath the membrane, and magnification
is limited by the distance between lens and fluorescent tissue. Additionally, this con-
struct did not permit selective manipulation of the nerve repair environment without
simultaneously altering that of the parent neuron.
To overcome the physical limitations of the Transwell construct, the walls of the
membrane insert were shortened to increase mechanical access to the membrane for
microsurgery and imaging. Fluidic isolation of motoneuron and regeneration compart-
ments was obtained by replacing the 6-well plate with a low-profile two-compartment
poly(dimethylsiloxane) (PDMS) base. Motor axons were conveyed from the motoneu-
ron compartment into the nerve repair compartment through reconstructed ventral
root that passed through a water-tight barrier. The result of these modifications is a
biocompatible organotypic system that facilitates tissue manipulation and photogra-
phy while permitting individual control of motoneuron and nerve repair environments.
Growth factor e↵ects can be studied in each compartment by adding growth factors
or by blocking growth factor function with antibodies or siRNA. This model also has
the potential to facilitate studies of Wallerian degeneration, myelination, and axonal
pathfinding.
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5.3 Materials and Methods
5.3.1 Fabrication of culture system
The completed device consists of two principle components: a PDMS reservoir for
culture medium that is divided into two compartments by a central partition, and a
superimposed Transwell membrane (Corning, Acton, MA) that provides a surface for
the growth of spinal cord and peripheral nerve co-cultures. The dimensions of these
components are illustrated in Figure 5.1.
PDMS reservoirs are replicas from a master mold created by micromachining a
negative relief of the device design into aluminum. Aluminum provides a robust sur-
face for molding that is both reusable and economical. The overall process flow for
creating the molds and assembling the device can be seen in Figure 5.2. The dimen-
sions of the PDMS reservoir are determined by the configuration of the Transwell
insert, the space required for media supply and exchange around the periphery of the
insert, and the PDMS surface area required for adhesion to a glass substrate. The
outer wall of the reservoir is circular with a 38 mm outer diameter and 33 mm inner
diameter. The Transwell is suspended over the media by the central partition, and
by two steps placed at 90 degrees to the axis of the partition. The partition is 28 mm
long and 1 mm tall, and bisects the device into two separate compartments. In order
to provide adequate support for the membrane and to ensure bonding to the glass
substrate, the partition is 5 mm wide along most of its length. At the center of the
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Figure 5.1: The two-compartment organotypic chamber consists of a PDMS reservoir
(A,B) and a modified Transwell insert (C). The reservoir is bisected by a partition to
create two fluidically isolated compartments. The Transwell insert is seated within
the insert so that the membrane surface contacts the surface of the PDMS partition
and two additional supports (D). To complete the fluidic isolation of the two com-
partments, the membrane is anchored to the partition with steel pins and bisected
along the center axis of the partition (E). A thin bead of silicon grease is then placed
to separate the cut edges of the membrane, insuring that no fluid can di↵use through
the membrane from one compartment to the other. A spinal cord segment is placed
in the motoneuron compartment; one reconstructed ventral root remains within that
compartment, and the other is directed across the grease barrier into the regeneration
compartment.
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Figure 5.2: Device Process Flow. Device design is micromachined into aluminum and
PDMS is used to create replicas. PDMS is poured into aluminum mold, cured, and
removed. The created replicas are plasma bonded to glass substrates. A Transwell
membrane is attached, bisected along its horizontal axis, and pinned to the device.
A spinal cord slice is placed on one side of the device, with a control nerve in the
same compartment and an experimental condition nerve traversing across the divider
of the device to the other compartment.
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device, a 3mm-long segment of the partition narrows to 2mm wide to maximize media
circulation to the nerve as it passes through the grease barrier between compartments
(Figure 5.1). To minimize sagging of the membrane beneath the spinal cord section,
the central narrow segment of the partition is flanked by two 1mm-wide buttresses
that extend perpendicular to its axis. A 0.25 mm thick film of PDMS connects the
base of the buttresses to enhance their bonding to the glass beneath, and to promote
the flow of media beneath the membrane so that bubbles do not form under the spinal
cord explant.
The Transwell membrane receives additional support from two 5mm-wide periph-
eral steps that are aligned on an axis at 90 to that of the partition (Figure 5.1A).
The lower stair step, which supports the Transwell insert, is 1mm above the floor of
the reservoir, and thus in the same plain as the surface of the partition; the upper
step is the full height of the device, and limits horizontal movement of the Transwell.
The inner edge of the upper step extends 2.5 mm horizontally from the inner wall,
creating a space 28 mm in diameter for the Transwell. Once a Transwell is placed
into the device, the spaces around the Transwell between the steps and the partition
serve as access points for media exchange.
Cross-linked PDMS (sold as Sylgard 184, Dow Corning, Midland, MI) is used to
make replicas of the reservoir using standard soft lithography techniques as described
in detail elsewhere (Xia and Whitesides, 1998). Figure 5.2 summarizes the device
process flow. Briefly, the base and crosslinker are mixed thoroughly in a ratio of
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10:1, and placed under vacuum to remove bubbles. The PDMS is then poured into
the aluminum master mold, leveled, and cured (cross-linked) at 85 C for at least 1
hour. Once removed from the mold, these replicas are cured for an additional 72
hours to minimize uncrosslinked components and impurities that could be toxic to
the spinal cord cultures. The PDMS replicas are then cleaned with ethanol, dried,
plasma bonded to 50 mm-diameter glass bottom dishes, and retreated with plasma
once bonded to ensure sterility.
The Transwell insert normally consists of a 24 mm diameter PTFE membrane with
3 µm size pores that is stretched over the open end of a 27mm-diameter polycarbonate
tube. In our preparation the tube is transected 1mm from the membrane surface
, leaving a 1mm thick rim of plastic that serves as a stretcher for the Transwell
membrane (Figure 5.1C). This modified Transwell is placed atop the PDMS reservoir
(Figure 1D), and anchored to the central PDMS partition with micropins fashioned
from .2 mm wide steel wire (Fine Science Tools, Foster City, CA). Once anchored,
the membrane is bisected with a no. 15 scalpel blade along the center axis of the
partition to separate the two compartments, and a thin bead of silicon grease is
interposed between the cut edges of the membrane to insure fluidic isolation (Figure
5.1E).
105
CHAPTER 5. COMPARTMENTALIZED ORGANOTYPIC NERVE REPAIR
MODEL
5.3.2 Preparing Organotypic co-cultures
Each assembled device was filled with enough serum-containing culture medium
(50% minimal essential medium (Gibco), 25% HBSS (Gibco), 25% heat-inactivated
horse serum (Hyclone, Logan UT), 25 mM HEPES, 35 mM D-glucose, 2 mM glu-
tamine, penicillin/streptomycin (Gibco), 70 ng/mL of GDNF (R&D Systems Inc,
Minneapolis, MN) to fill the bottom of the device and wet the membrane, approxi-
mately 500 µL per compartment.
Spinal cords were obtained from mice expressing a green variant of yellow flu-
orescent protein in sensory and motor neurons [186]. Transgenic B6.Cg-Tg(Thy1-
YFP)16Jrs/J animals (Jackson Laboratories, Bar Harbor, ME) were maintained as
heterozygous breeders (line thy1-YFP-H). Spinal cord sections were obtained from
day 3 or day 4 postnatal mouse pups using a modified version of described meth-
ods [185]. Spinal cords were dissected from the pups, and their dura and root frag-
ments removed. The lumbar spinal cord was cut into 350 µm-thick slices with a
McIllwain tissue chopper (Ted Pella, Redding, CA). A single slice was placed in each
device 2-3mm from the grease barrier with the motoneuron pools oriented closest to
the barrier. The median and ulnar nerves of the sacrificed pup were harvested and
their cut ends were each abutted to one of the two motor neuron pools in the spinal
cord section to reconstruct ventral roots. One ventral root extended within the same
compartment as the spinal cord parallel to the partition, while the other crossed the
partition into the second compartment. Cultures were incubated at 37 C in a humid-
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ified atmosphere containing 5% CO2. Medium was changed every other day, with the
first two changes including 70 ng/ml of GDNF.
The compartment containing the spinal cord section is referred to as the motoneu-
ron compartment, and the contralateral compartment is referred to as the growth cone
or regeneration compartment. Applying a treatment to the motoneuron compartment
will alter the environment of all motoneurons as well as the axons regenerating in that
compartment, but will not change the environment in the regeneration compartment.
Similarly, changing the environment in the regeneration compartment will not alter
that of any motoneurons, or of the nerve regenerating in the motoneuron compart-
ment.
Nerve repairs were performed five to seven days after the co-cultures had been
established, by which time the ventral roots were re-populated with fluorescent axons.
The reconstructed ventral roots were transected with microscissors 3-5 mm from the
spinal cord. Median and ulnar nerves harvested from wildtype (C57BL) donor mice
were then sharply transected and their cut surfaces opposed to those of the ventral
roots. The axons in these grafts do not contain fluorescent protein, so all fluorescence
in the grafts will represent regenerating axons.
5.3.3 Testing Fluidic Isolation
We sought to confirm the fluidic isolation of the two compartments. Trypan
blue (Gibco, Grand Island, NY) was applied to the nerve repair compartment in
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cultures that had already been maintained for 3 weeks, with regular media exchange
every other day. The stock 0.4% by w/v Trypan blue was diluted to 0.01%. The
motor neuron compartment continued to contain culture media. Cultures (n=3) were
monitored over an additional two days.
5.3.4 Testing Physiological Integrity
Retrograde labelling was used to determine the relative ability of motoneurons to
project axons through the grease barrier and into the regeneration compartment. The
reinnervated ventral root in the regeneration compartment was transected sharply,
and its cut end placed on a 1 mm square of stretched Parafilm. Crystals of Fluoro
Ruby (Molecular Probes, Eugene, Oregon) were placed on the freshly-cut end of
the graft for 30 minutes, after which the remaining tracer was carefully removed to
prevent contamination of the medium.
We tested the physiologic integrity of the regeneration compartment by adding
Nocodazole (Sigma Aldrich, St. Louis, MO) to inhibit microtubule polymerization.
The Nocodazole was dissolved in dimethylsulfoxide (DMSO) (Quality Biological,
Gaithersburg, MD) to a concentration of 33.3 mM, then further diluted in media
to working concentrations. Based on previous studies, a 1µM concentration of Noco-
dazole was used initially. When this was found to have little di↵erential e↵ect, the
nerves in both compartments were recut, and a 5 µM dose of Nocodazole was applied
to the regeneration compartment. The media was replaced every other day in both
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compartments for 1 week (n=3).
To evaluate the permeability of cultured nerve to large molecules such as antibod-
ies and growth factors, we added FITC- dextran (150 kDa; Sigma-Aldrich, St. Louis,
MO) to the media at a concentration of 1mg/ml for 24h. Nerve segments were then
fixed for 2 h in 4% paraformaldehyde in Sorensen’s bu↵er, stored overnight in 20%
sucrose in Sorensen’s bu↵er, and sectioned longitudinally at 10µM with a cryostat.
Slides were then overlaid with coverslips using DPX (Sigma-Aldrich) to minimize
fluorescent background.
5.3.5 Imaging
Real-time images were obtained with a Nikon Eclipse E600 fluorescent microscope
equipped with a motorized stage, a spot CCD Camera, and an on-stage incubator
that maintained required environmental culture conditions, including temperature,
CO2 level, and humidity, to enable long-term monitoring and image acquisition. Us-
ing NIS-Elements Microscope Imaging Software, a stack of images was generated at
progressive focal planes through the specimen. These stacked images were then flat-
tened to a single image. Photoshop was used to adjust the contrast and brightness
of individual flattened images and to create composites of several adjacent images.
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5.4 Results
5.4.1 Viability of organotypic cultures in compart-
mentalized PDMS reservoir devices
Spinal cord and peripheral nerve are cultured on the upper surface of the mem-
brane. They are nourished by underlying media that di↵uses up through membrane
pores, and have direct access to oxygen on their exposed upper surfaces. The media
is replaced every two days through openings around the outer circumference of the
device. Fluorescent images of a 15-day culture are shown in Figure 5.3. Motor neuron
pools are densely populated with neurons that show no morphologic signs of degener-
ation (Figure 5.3B), indicating adequate nourishment and oxygen supply. Similarly,
motor axons in both compartments appear healthy in that they are smooth, contin-
uous fibers with no beading or interruptions that would indicate degeneration. The
portion of the reconstructed ventral root that conveys axons into the regeneration
compartment does not receive direct nourishment, as it is isolated from underlying
media by the grease barrier. Axons in this area appear healthy none the less, sug-
gesting that longitudinal di↵usion of media within the nerve is su cient to maintain
viability over short distances.
Reconstructed ventral roots are populated with fluorescent axons 5-7 days after the
cultures are set up, an interval similar to that observed in single-compartment cultures
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Figure 5.3: Reconstruction of an organotypic preparation during nerve graft reinner-
vation (left and bottom) from a representative 15-day culture. Dotted lines indicate
location of the barrier. A. Axons that have traversed the vertical nerve graft growing
out onto the membrane surface. B. Motoneuron pool that projects axons across the
barrier into the regeneration compartment remains healthy. C. The ventral root-graft
interface.
111
CHAPTER 5. COMPARTMENTALIZED ORGANOTYPIC NERVE REPAIR
MODEL
[10]. Once this has occurred, nerve repairs are performed in both compartments
by transecting the ventral roots and opposing nerve grafts from wild type mice to
their cut surfaces (Figure 5.3C). Reinnervation of the grafts was comparable in both
compartments, as shown by the similar calibre of the reinnervated grafts (Figure 5.3).
Grafts were reinnervated in 4-6 days, a slightly longer time than that the average 2-3
days observed in single-compartment cultures. Many axons cross to reinnervate the
graft, but those not directly opposed to distal nerve grow out on the membrane in
both compartments.
5.4.2 Fluidic Isolation
A critical attribute of the culture device is the ability to maintain fluidic isolation
of the two compartments for the duration of an experiment. We reasoned that leakage
was most likely to occur after the device had been handled several times for media
exchange. We thus placed Trypan blue in the nerve repair compartment of devices
that had been maintained for 3 weeks. The devices were observed closely for an ad-
ditional 48 hours, and no leakage was observed (Figure 5.4). The device is symmetric
along the bridge, with motoneuron and nerve repair compartments identical to each
other, thus selection of a compartment for motoneuron or nerve repair is random.
To confirm di↵usion did not occur in either direction, we have also filled randomly
selected compartments in multiple devices maintained for several weeks with dye and
investigated for di↵usion, as well as alternated which compartment dye was applied
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Figure 5.4: Fluidic Isolation in Device. The extent and duration of fluidic isolation
were tested by placing a solution of Trypan blue in the regeneration compartment.
A. View of an entire device, showing confinement of Trypan blue to the regeneration
compartment after 3 weeks, a duration longer than most of our experiments. B.
Darkfield view of the same device at higher magnification to illustrate the location of
the spinal cord segment and ventral roots in relation to the grease barrier and steel
pins.
in devices containing cultures. The results were identical to those pictured in Figure
5.4A.
5.4.3 Physiologic integrity of the dual-chamber sys-
tem
FluoroRuby was applied to axons in the regeneration compartment to label their
cell bodies in the motoneuron compartment. This tracer is taken up by cut axons, is
retrogradely transported through the nerve and across the barrier, and accumulates
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within parent motoneurons. During the process of regeneration, individual motoneu-
rons may generate multiple collateral sprouts [187]. A small number of motoneurons
could thus fully reinnervate the reconstructed ventral roots. In the dual-chamber
system, all YFP-positive motoneurons in the pool that projected to the regenera-
tion compartment were also labelled with Fluoro-Ruby, indicating that they had all
projected axons across the barrier (Figure 5.5). Furthermore, retrograde labelling
was seen only in the motoneuron pool, indicating that other neuron types had not
projected axons into the graft.
To test the physiologic integrity of the two compartments, we blocked microtubule
polymerization in the regeneration compartment with 5 µM Nocodazole. The repre-
sentative images in Figure 5.6 were taken after one week of Nocodazole exposure. Ax-
Figure 5.5: Fluorescent images of the motoneuron pool used to populate the regener-
ation compartment. All YFP-positive motoneurons in the pool (A) are also labeled
with Fluoro-ruby (B). Axons in the regeneration compartment are thus linked to the
entire motoneuron pool, rather than to a subset of neurons that might di↵er in some
way from the others. Close inspection reveals that not all motoneurons in the pool
expressed YFP, as occasional motoneurons are labeled with Fluoro-Ruby alone.
114
CHAPTER 5. COMPARTMENTALIZED ORGANOTYPIC NERVE REPAIR
MODEL
Figure 5.6: The ends of reconstructed ventral roots that had been transected 1 week
previously. Nocodazole was added to the regeneration compartment at the time of
nerve transection. In the untreated motoneuron compartment robust regeneration is
evident, with many axons growing out on the membrane surface (A). In the treated
regeneration compartment, however, axons are degenerating (B).
ons in the untreated motoneuron compartment regenerated vigorously (Figure 5.6A),
while those in the treated regeneration compartment were degenerating (Figure 5.6B).
Isolation of the treatment e↵ect to the regeneration compartment was confirmed by
the healthy appearance of both motoneuron pools (Figure 5.7).
Cultured peripheral nerve that had been exposed to 150kDa FITC-dextran at a
concentration of 1 mg/ml for 24 h was uniformly fluorescent when viewed through a
FITC filter, confirming that large molecules could access the endoneurial space.
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Figure 5.7: Motoneurons are abundant and healthy-appearing in both pools, indi-
cating that Nocodazole has not leaked from the regeneration compartment into the
motoneuron compartment.
5.5 Discussion
In our dual-chamber organotypic culture platform, YFP-expressing motoneurons
in one chamber project their axons into a second chamber through a three-dimensional
segment of peripheral nerve. Nerve repair is then performed in the second chamber
by transecting the axon-bearing nerve and joining it to an additional nerve segment.
In this system, the environment of either growth cone or motoneuron can be manip-
ulated individually to localize signaling events that contribute to regeneration. The
consequences of these manipulations can then be monitored by repeated fluorescence
imaging of the YFP-positive axons as they regenerate.
Our construct is the three-dimensional descendant of the Campenot Chamber, a
system for isolating neuronal cell bodies from their regenerating axons in monolayer
cell culture [4]. In this on-slide device, axons elongate beneath a grease barrier that
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separates neuronal and growth cone compartments by following grooves scratched
onto the glass surface. The Campenot Chamber was used extensively in early studies
of growth factor signaling. In cultures of NGF-sensitive sympathetic neurons, for in-
stance, Campenot demonstrated that NGF promoted neurite outgrowth when applied
to the growth cone, but not when applied to the neuronal cell body [188]. Adult DRG
neurons could also be studied because of their relative ease of culture, but di culties
in culturing motoneurons precluded their use with this device [4, 189–191].
More recently, it has become possible to isolate neurons from their axonal growth
cones by controlling the flow of medium rather than by imposing a physical barrier
between them [5]. In these microfluidic devices, two fluid-filled chambers are con-
nected by microchannels that direct axon growth. Because of the high resistance to
fluid flow inherent in such minute channels, a small but sustained flow of medium
is su cient to counteract di↵usion in the opposite direction, e↵ectively preventing a
substance added to the downstream chamber from entering the upstream chamber.
These types of devices and their derivatives have been useful in a variety of neurobi-
ology studies, including examination of local toxic e↵ects, such as that of paclitaxel
on sensory axons, as well as those of focal injury [7, 8, 24, 82, 86]. These devices also
range from those that support multiple parallel experiments in a single device to those
that allow for single axon injury [82,100]. Although monolayer cell culture techniques
that isolate neurons from their growth cones have been critical to our understanding
of intracellular processes, they cannot model the complex three-dimensional inter-
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actions necessary for peripheral nerve regeneration. Furthermore, these techniques
are di cult to apply to motoneurons because of their need for trophic support from
surrounding glia [190, 192].
Organotypic co-culture of spinal cord and peripheral nerve overcomes many of the
shortcomings of monolayer techniques. Motoneurons that retain contact with glia and
other motoneurons in spinal cord slices support robust regeneration and survive for up
to three months [185]. Similarly, peripheral nerve survives in culture, and maintains
the three-dimensional relationship of Schwann cells and basal lamina critical to the
support of axon regeneration [193,194]. In our previous work, we co-cultured these two
tissues and were able to innervate segments of peripheral nerve with motor axons [10].
The ability to contain these axons within the confines of a peripheral nerve segment,
and thus independent of the membrane surface, suggested the possibility of using
nerve as a flexible conduit to direct axons from one compartment to another.
Our initial model of organotypic nerve repair utilized the Transwell culture sys-
tem [10]. In the current model, a shortened Transwell insert is supported by a two-
chamber PDMS reservoir. These modifications enhance the quality of imaging, fa-
cilitate surgical manipulation of the tissues, and create separate motoneuron and re-
generation compartments. In the Transwell system, cultures are imaged from below,
through both the plastic bottom of the dish and 1mm of culture medium. Reducing
the height of the insert facilitates high resolution imaging from above the membrane,
eliminating the distortion caused by plastic and medium and allowing the microscope
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objective to get closer to the tissue. Without the high walls surrounding the insert it
is easier to manipulate tissues on the membrane with microsurgical instruments.
The greatest challenge in modifying our original model was to develop a partition
that would simultaneously provide fluidic isolation of two compartments yet support
the transfer of living axons from one chamber to the other. After trying several
configurations, we succeeded by bisecting the membrane along the axis of the partition
and separating the edges with a thin barrier of silicon grease. The consequences of
modifying the membrane in this way included the need to pin the membrane to the
partition and support it with lateral buttresses to keep it taut beneath the spinal
cord and nerve segments.
As a result of these modifications, we have developed the first two-compartment
organotypic spinal cord and peripheral nerve co-culture platform. We have demon-
strated that motoneurons remain viable within this system, and extend their axons
from one compartment to the other. Furthermore, we have confirmed the physio-
logic integrity of the system by applying nocadazole to inhibit axonal regrowth in one
compartment without a↵ecting axons or motoneuron cell bodies in the other compart-
ment. With these advances, we can now isolate growth factor e↵ects to regenerating
motor axons without influencing their parent neurons. This can be done by adding
the growth factor of choice to the regeneration compartment, or by perturbing growth
factor function with antibodies or specific inhibitors. Additionally, work is ongoing
in our laboratory to combine spinal cord and DRG cultures to produce mixed nerve
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for studies of regeneration specificity.
5.6 Conclusions
We have developed a two-compartment culture device for the study of motor axon
regeneration after nerve repair. The device consists of a two-compartment PDMS base
to which a collagen-coated membrane is attached. We have demonstrated that such a
device can be used to support viable spinal cord and peripheral nerve co-cultures, to
perform nerve repair in vitro, and to maintain fluidic isolation between motoneuron
and growth cone compartments. This device is ideal for the study of growth factor




Discussion and Future Directions
6.1 Summary and Significance of Results
The overall objective of this dissertation was to develop and apply in vitro devices
that enable precise control over the immediate environment of injured peripheral
axons in order to determine localized e↵ects of both degenerative and regenerative
compounds. These devices enable a more complete understanding of peripheral axon
injury and regeneration. This dissertation includes microfluidic devices utilized to
determine the site of action of toxic, neuroprotective, and neurotrophic e↵ects in
peripheral axons, and culminates in the development of the first compartmentalized
tissue-level nerve repair platform.
The study in Chapter 3 deals with chemical injury and aimed to examine the
localized e↵ects of the degenerative chemotherapeutic agent paclitaxel and determine
121
CHAPTER 6. DISCUSSION AND FUTURE DIRECTIONS
the site of action of the theorized neuroprotective glycoprotein hormone erythro-
poietin through the utilization of a compartmentalized microfluidic chamber. We
demonstrate that paclitaxel is much more toxic when applied directly to the axon
versus the cell body, causing degeneration within 24 hours. We also demonstrate
that erythropoietin is capable of rescuing axons from this degenerative e↵ect, in-
terestingly through either cell body or axonal application. Importantly, this study
demonstrates that axonal degeneration through local mechanisms can be counteracted
through cellular mechanisms, which has implications for drug therapy development
for polyneuropathies.
Chapter 4 first aims to more fully characterize the di↵usion profile along mi-
crochannels of the chamber and establish su cient height fluid height di↵erences for
su cient hydrostatic pressure for use in longer term experiments. Through theoret-
ical, computational, and experimental verification, a height di↵erence of 2 mm was
su cient to localize compounds of relevant molecular weight to one side of the axonal
chamber, and needed to be replenished every 24 hours to maintain isolation. Once
this di↵usion profile was established, the device was used as an injury device, where
gently scratching the surface of the open axonal compartment was su cient to cause
a focal axonal injury and subsequent degeneration. The GDNF family of ligands was
investigated as enhancers of regeneration post-injury due to their therapeutic poten-
tial. Interestingly, we find that all tested GDNF ligand family members have an e↵ect
on enhancing regeneration. As expected, GDNF was the most potent of these, with
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enhanced e↵ectiveness when applied to the cell body side. This study demonstrates
the importance of understanding axon specific or cell body specific e↵ects of growth
factors necessary for future growth factor-based therapies for enhancing regeneration.
Extension of these experiments to DRG explants demonstrates that the enhanced
complexity at the tissue-level, including the presence of more support cells and ECM
components, may a↵ect or mask the regenerative e↵ects of exogenous GDNF.
Finally, Chapter 5 deals with the development of a two-compartment tissue-level
device that enables the control of the local environment of regenerating adult motor
axons within a three-dimensional nerve repair model. It is the first device of its kind
as a two-compartment spinal cord and peripheral nerve co-culture platform. Spinal
cord is plated in the motor neuron compartment, while one nerve is placed in the same
compartment to serve as a built-in control, and another travels across a barrier into the
other chamber for examining localized e↵ects. We have optimized the device design to
ensure motor neuron viability while maintaining functional fluidic isolation between
the compartments. We demonstrate successful axonal regrowth within peripheral
nerve over the barrier, and robust and comparable regeneration across nerve repairs
performed in both compartments. The physiological integrity of the device has been
confirmed. First, this confirmation was done through dye isolation. Next, we added
nocodazole, another chemotherapeutic agent known to cause axonal degeneration,
and demonstrated that its e↵ects could be localized to one compartment.
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6.2 Future Directions
There is a need to study neurons in an environment that more closely resembles
their intrinsic in vivo environment, where cell bodies and distal axonal ends may
experience drastically di↵erent environments. This di↵erence has implications for
drug delivery for therapies aimed at polyneuropathies in terms of site of application,
as well as for administration of growth factors in order to achieve prime regeneration
enhancement. The studies performed in this thesis further demonstrate site specific
e↵ects and establishes a platform that more closely resembles a clinical nerve repair
environment.
Developing a way to guide regenerating axons is a necessary next step in the future,
as misdirection of regenerating axons remains a predominant obstacle to functional
recovery post-injury. To enable incorporation into our two-compartment organotypic
chamber, which has an intrinsic directionality due to the collagen-coated Teflon mem-
brane, we have examined the use of gels on top of which to grow the axons, including
collagen-laminin gels, as discussed in Chapter 4. Currently available technologies also
enable the use of gels with pre-established growth factor gradients, and these can be
used to examine the di↵erence between soluble and bound cues. Current studies are
underway combining spinal cord slice and DRG ganglion cultures so that both extend
their axons into one femoral nerve graft. As an extension of guidance studies, de-
veloping a system to separate sensory versus motor axons with specificIty is another
goal. Motor neurons and sensory neurons may also exert an e↵ect on each other in
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terms of both tropism and trophism and this is something that can be investigated
within our device.
There are several additional exciting areas for future studies. These areas include
alternative means of guidance, multiplexing devices so that more experiments can be
done in parallel, incorporating electrodes within devices, and enabling other modes of
injury within devices. There has been evidence that non-uniform AC fields can be used
to dynamically control axonal outgrowth in vitro within microfluidic devices [195].
This phenomenon can be investigated within our tissue-level platform to examine if
this is phenomenon is repeatable in an environment that more closely represents the in
vivo. Incorporation of advances in high-throughput patterning can be used to create
massively parallel arrays of single axons [196]. Patterned 3D neural networks are
another exciting area of study, and extension of this technology to tissue level systems
can provide an additional way to mimic the in vivo three-dimensional environment
[197]. Another exciting evolution of both the cellular and organotypic devices can
include the incorporation of microelectrode arrays which would enable functional
studies of regenerating neurons by allowing for stimulation and recording of neuronal
activity. The feasibility of these types of microfluidic arrays at both the two- and
three-dimensional level within microfluidic neuronal culture and tissue culture has
been recently demonstrated, and the natural progression to incorporate these within
an injury platform would allow for studies that confirm if regenerating axons within
these devices are quantifiably functional [198, 199]. Development of the organotypic
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nerve injury device to incorporate other modes of injury would also be valuable. For
example, in a recent brain-on-a-chip device, stretch injuries were modeled by applying
culturing brain slices on a flexible substrate and applying a pressure underneath [200].
This technique can be extended to our two-compartment platform, which contains a
flexible PDMS base that is easily modifiable.
Continuing to advance three-dimensional in vitro models of nerve injury and re-
generation would enable development of future clinical therapies for improving quality
of life and regain of function for those su↵ering from peripheral nerve injuries. Next
generation devices are expected to continue to improve in vivo representation, as basic
science promotes the development of advanced devices and advanced devices promote
the development of cellular discoveries. Related advances in three-dimensional tissue
and organ printing, for example, have additional exciting implications for a bottom
up approach to developing accurate in vitro models. Future developments in the area
of peripheral nerve injury research are expected to allow for a deeper understanding
of the mechanisms that underlie both degeneration and regeneration, and enable the











1. Silane treat master wafer under vacuum (for microfluidic devices)
2. Mix Sylgard 184 (Polydimethylsiloxane (PDMS))in a ratio of 10:1 base:cross-
linker for at least 5 minutes, vigorously until well aerated.
(a) For microfluidic chambers: 50g base: 5g cross-linker
(b) For single and dual chamber organotypic devices 20g base: 2g cross-linker
3. De-gas the aerated mixture in desiccator for 15-20 minutes
4. Open desiccator to remove remaining bubbles. Repeat degassing if necessary.
5. Pour mixture onto wafer or mold
6. Cover and let sit for 5 minutes to remove any bubbles from pouring.
7. Place in oven and bake at 85 C
(a) For microfluidic chambers: 1-2 hours
(b) For organotypic devices: 1 hour
8. Cool and remove PDMS from wafer/mold. For organotypic devices, place
PDMS back into oven to continue baking to remove impurities for at least
72 hours




1. Ensure devices are clean
(a) If microfluidic chambers, tape clean
(b) Place in sonicator in 100% ethanol, channel side up (the side that will
bond to glass up)
(c) Set to sonic, time: 5 minutes
(d) Remove from ethanol near hood, place on foil to dry
2. If microfluidic chambers, tape clean again if necessary or to ensure tight bonding
3. Open vent to plasma machine
4. Place device channel side up (or flat surface up for organotypic devices) glass
slide or glass bottom dish (sterile and sonicated in ethanol)inside plasma ma-
chine
5. Close door to plasma chamber, close vent, turn on vacuum pump and pressure
gauge, and ensure that oxygen tank is open
6. Let pressure come down to below 150 mTorr
7. Slowly open gas valve to increase pressure to around 500 mTorr
8. Turn on plasma, and switch power to high
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9. Check that plasma light is purple in color (reflects energy level of plasma).
Adjust pressure if necessary
10. Set timer to 1 minute and 25 seconds
11. Turn o↵ plasma when timer runs out, turn o↵ pump, turn o↵ gas, and vent the
chamber taking care not to open valve too fast
12. Work quickly once exposed to atmosphere, flip device over and attach onto
exposed side of glass substrate, press to bond
13. For organotypic devices, plasma treat bonded devices once more for sterility
bake for 5 minutes immediately post bonding to ensure strength of bond. For
microfluidic devices, can bake 20 minutes to ensure strong bonding, or utilize
temporary hydrophilicity immediately post bonding to coat devices with ECM
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A.4 Spinal cord and Peripheral Nerve Co-
Culture
1. Obtain mouse pups (p3 to p5 age range)
2. Prepare 70% ethanol solution for submerging dissection tools
3. Decapitate first pup with scalpel
4. Obtain nervous tissue sample from decapitated head and place on microscope
slide
5. Check tissue under fluorescent scope to confirm fluorescence if using YFP mice
6. Pin down pup supine
7. Obtain median an ulnar nerves from each arm of pup before proceeding to spinal
cord dissection
(a) Remove superficial skin on arm to locate nerves
(b) Dissect median and ulnar nerves from brachial plexus to wrist (as far as
possible)
(c) Place nerves in dissection media, separate, and clean
8. Excise volar skin
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9. Cut through ribs bilaterally approaching and remove organs in order to expose
spinal cord
10. Pin back any tissue or organs at tail to increase visibility
11. Carefully open spinal canal, taking care not to damage inner spinal cord tissue
12. Once bone is removed, run forceps carefully down each side of cord to avulse
roots
13. Carefully life spinal cord tissue from caudal end and continue to excise roots as
lifting up and moving distally
14. Place cord in dissection medium
15. Carefully dissect o↵ dura
16. Place spinal cord on plastic transparency for use on tissue chopper
17. Ensure that tissue chopper blade is installed correctly and is parallel to the
chopper plate and perpendicular to the spinal cord
18. Ensure spinal cord is relatively straight
19. Check that the tissue chopper is set to 350 micron thick slices
20. Adjust chopper start point so that entire cord will be cut in one run
21. Start machine and hold plastic down during run
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22. Once cord is cut, invert plastic sheet into dissection media, rolling spinal cord
sections into contact with media to ensure that they come o↵
23. Separate any sections that do not naturally separate and ensure that sections
sink instead of float as floating will dry out sections
24. Cut a p200 pipette tip so that opening is large enough for entrance of a spinal
cord section
25. Set pipette to approximately 150 µL to pull in individual sections and place
them directly on a membrane
26. If required, move spinal cord into place
27. Identify ventral horn by locating central canal (ventral horn is closer to central
canal)
28. Place a nerve at each ventral horn, abutting the cut nerve end to the spinal
cord as closely as possible
29. Within two days, can check health of motor neurons
30. Allow enough time for adequate reinnervation of nerve (approximately 1 week)
31. Perform nerve injury by performing a transection in culture




A.5 Coating Devices for DRG cultures
1. Dilute either Poly-L-Lysine (PLL) or Poly-D-Lysine (PDL) to 1 mg/mL stock
solution in ultra pure water
2. Freeze unused PLL or PDL in 1 mL aliquots
3. Dilute solution further to 100 µg/mL to obtain working concentration
4. Clear channels of the device
(a) Apply ethanol to one side of device, let flow through channel and enter
other compartment of device. Do a minimum of 3 washes with water
(alternating sides) to ensure removal of ethanol
(b) Alternatively, due to potential toxicity of residual ethanol, utilize hy-
drophilicity immediately post bonding to encourage coating of device for
next step
5. Apply either PLL or PDL to one side of device, keeping one side of device
slightly elevated to encourage flow
6. Let solution flow through channels and coat for at least 4 hours at room tem-
perature or overnight at 4 C
7. Remove solution and replace with laminin in PBS (or ultra pure water) at a
concentration of 10 µg/mL (good range between 1-10 µg/mL)
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8. Let coat at least 4 hours in incubator
9. Remove laminin, wash 3x (alternating sides) with PBS, and do final wash with
media
10. Prior to cell loading, remove media from from both sides, leaving enough to
continuously coat the surface of the device, and load cells
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A.6 Thin Collagen Gel Sheet Fabrication
1. Use a PDMS mold with a well roughly 50-100 microns deep depending on thick-
ness needs
2. Sterilize PDMS mold with ethanol, 20 minutes
3. Perform all solution preparation on ice under sterile conditions
4. Mix Collagen I, Rat tail (Gibco), 7.5% sodium bicarbonate and 10X PBS in a
8:1:1 ratio
5. If laminin required, add 10 µg/mL to solution
6. Vortex solution
7. Place solution on ice for 20 minutes before loading solution into PDMS molds
8. Load gel with p200 pipet, starting in 200 µL increments
9. Place gels in incubator at 37 C for 2 hours to ensure adequate gelation
10. Additional time may be necessary to dry gels. Note that once mold is partially
removed, gels will dry very quickly and may become di cult to handle
11. Once gels are sti↵ enough to handle, cut gels to necessary dimensions from
formed sheets and place under transected nerve
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platform to study injury and regeneration of single axons,” Lab Chip, vol. 9,
no. 17, pp. 2576–2581, 2009.
[101] D. K. Cullen and M. C. LaPlaca, “Neuronal response to high rate shear de-
formation depends on heterogeneity of the local strain field,” J Neurotraum,
vol. 23, no. 9, pp. 1304–1319, 2006.
[102] F. Kurth, K. Eyer, A. Franco-Obregón, and P. S. Dittrich, “A new mechanobi-
ological era: microfluidic pathways to apply and sense forces at the cellular
level,” Curr Opin Chem Biol, vol. 16, no. 3–4, pp. 400–408, 2012.
[103] E. Ellis, J. McKinney, K. Willoughby, S. Liang, and J. Povlishock, “A new
model for rapid stretch-induced injury of cells in culture: characterization of
the model using astrocytes,” J Neurotraum, vol. 12, no. 3, pp. 325–339, 1995.
[104] D. H. Smith, J. A. Wolf, and D. F. Meaney, “A new strategy to produce sus-
tained growth of central nervous system axons: continuous mechanical tension,”
Tissue Eng, vol. 7, no. 2, pp. 131–139, 2001.
[105] T. Wu, S. Mohanty, V. Gomez-Godinez, L. Z. Shi, L.-H. Liaw, J. Miotke,
R. L. Meyer, and M. W. Berns, “Neuronal growth cones respond to
153
BIBLIOGRAPHY
laser-induced axonal damage,” J R S Interface, 2011. [Online]. Available:
http://rsif.royalsocietypublishing.org/content/early/2011/08/04/rsif.2011.0351.abstract
[106] G. M. Walker and D. J. Beebe, “A passive pumping method for microfluidic
devices,” Lab on a Chip, vol. 2, no. 3, pp. 131–134, 2002. [Online]. Available:
http://dx.doi.org/10.1039/B204381E
[107] C. R. Kothapalli, E. van Veen, S. de Valence, S. Chung, I. K. Zervantonakis,
F. B. Gertler, and R. D. Kamm, “A high-throughput microfluidic assay to
study neurite response to growth factor gradients,” Lab Chip, vol. 11, no. 3, pp.
497–507, 2011.
[108] R. A. C. Hughes, “Peripheral neuropathy,” BMJ, vol. 324, no. 7335, pp. 466–
469, 2 2002.
[109] J. W. Mold, S. K. Vesely, B. A. Keyl, J. B. Schenk, and M. Roberts, “The
prevalence, predictors, and consequences of peripheral sensory neuropathy in
older patients,” The Journal of the American Board of Family Practice, vol. 17,
no. 5, pp. 309–318, 2004.
[110] D. Lacomis, “Small-fiber neuropathy,” Muscle & nerve, vol. 26, no. 2, pp. 173–
188, 2002.
[111] M. Periquet, V. Novak, M. Collins, H. Nagaraja, S. Erdem, S. Nash, M. Freimer,
154
BIBLIOGRAPHY
Z. Sahenk, J. Kissel, and J. Mendell, “Painful sensory neuropathy prospective
evaluation using skin biopsy,” Neurology, vol. 53, no. 8, pp. 1641–1641, 1999.
[112] P. J. Dyck, J. L. Karnes, P. O’Brien, H. Okazaki, A. Lais, and J. Engelstad,
“The spatial distribution of fiber loss in diabetic polyneuropathy suggests is-
chemia,” Annals of neurology, vol. 19, no. 5, pp. 440–449, 1986.
[113] I. Merkies, P. Schmitz, F. Van der Meche, J. Samijn, and P. Van Doorn, “Con-
necting impairment, disability, and handicap in immune mediated polyneu-
ropathies,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 74, no. 1,
pp. 99–104, 2003.
[114] R. Lipton, S. Apfel, J. Dutcher, R. Rosenberg, J. Kaplan, A. Berger, A. Einzig,
P. Wiernik, and H. Schaumburg, “Taxol produces a predominantly sensory
neuropathy,” Neurology, vol. 39, no. 3, pp. 368–368, 1989.
[115] Z. Sahenk, R. Barohn, P. New, and J. R. Mendell, “Taxol neuropathy: elec-
trodiagnostic and sural nerve biopsy findings,” Archives of neurology, vol. 51,
no. 7, pp. 726–729, 1994.
[116] P. B. Schi↵ and S. B. Horwitz, “Taxol stabilizes microtubules in mouse fibroblast
cells,” Proceedings of the National Academy of Sciences, vol. 77, no. 3, pp. 1561–
1565, 1980.
[117] ——, “Taxol assembles tubulin in the absence of exogenous guanosine 5’-
155
BIBLIOGRAPHY
triphosphate or microtubule-associated proteins,” Biochemistry, vol. 20, no. 11,
pp. 3247–3252, 1981.
[118] N. B. Laferrière, T. H. MacRae, and D. L. Brown, “Tubulin synthesis and
assembly in di↵erentiating neurons,” Biochemistry and cell biology, vol. 75,
no. 2, pp. 103–117, 1997.
[119] G. Cavaletti, G. Tredici, M. Braga, and S. Tazzari, “Experimental peripheral
neuropathy induced in adult rats by repeated intraperitoneal administration of
taxol,” Experimental neurology, vol. 133, no. 1, pp. 64–72, 1995.
[120] G. Melli, C. Jack, G. L. Lambrinos, M. Ringkamp, and A. Höke, “Erythro-
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vala, M. Saarma, and P. T. Männistö, “Heparin-binding determinants of gdnf
reduce its tissue distribution but are beneficial for the protection of nigral




[158] D. Narantuya, A. Nagai, A. M. Sheikh, J. Masuda, S. Kobayashi, S. Yamaguchi,
and S. U. Kim, “Human microglia transplanted in rat focal ischemia brain
induce neuroprotection and behavioral improvement,” PLoS One, vol. 5, no. 7,
p. e11746, 2010.
[159] R. H. K. Lee, W. L. Wong, C. H. Chan, and S. Y. Chan, “Di↵erential e↵ects of
glial cell line-derived neurotrophic factor and neurturin in ret/gfr↵1-expressing
cells,” Journal of neuroscience research, vol. 83, no. 1, pp. 80–90, 2006.
[160] G.-S. Liu, J.-Y. Shi, C.-L. Lai, Y.-R. Hong, S.-J. Shin, H.-T. Huang, H.-C. Lam,
Z.-H. Wen, K.-S. Hsu, C.-H. Chen et al., “Peripheral gene transfer of glial cell-
derived neurotrophic factor ameliorates neuropathic deficits in diabetic rats,”
Human gene therapy, vol. 20, no. 7, pp. 715–727, 2009.
[161] L. Zhang, Z. Ma, G. M. Smith, X. Wen, Y. Pressman, P. M. Wood, and X.-M.
Xu, “Gdnf-enhanced axonal regeneration and myelination following spinal cord
injury is mediated by primary e↵ects on neurons,” Glia, vol. 57, no. 11, pp.
1178–1191, 2009.
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